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ABSTRACT 
 
Construction of functional supramolecular nanoassemblies has attracted great deal of 
attention in recent years for their wide spectrum of practical applications. Mesoporous silica 
nanoparticles (MSN) in particular were shown to be effective scaffolds for the construction 
of drug carriers, sensors and catalysts. Herein, we describe the synthesis and characterization 
of stimuli-responsive, controlled release MSN-based assemblies for drug delivery. 
First we report on devising a functional UV light responsive delivery system for 
doxorubicin, a widely used anticancer drug. A positively charged drug molecule is adsorbed 
on the surface of the MSN through charge interaction and hydrogen bonding with surface 
silanols. The surface of MSN contained nitroveratryl carbamate protected aminopropyl 
moieties which undergo deprotection upon irradiation with UV light. The drug delivery 
principle is based on charge repulsion between UV light-generated, positively charged 
propylammonium ions and positively charged doxorubicin molecules. Release of the drug 
also increases by lowering the pH from 7.4 to 6.4. This result is beneficial for selective drug 
delivery to tumor tissues, as most tumor tissues have low extracellular pH value.   
We then set forth to develop magnetic analogues of mesoporous silica nanoparticles 
in order investigate possibilities for magnetic field induced targeted drug delivery. A series of 
new materials was obtained with radial and hexagonal packing of the mesopores, containing 
magnetic nanoparticles inside the core of the mesoporous silicate framework. We monitored 
the ability of the magnetic materials to adsorb and deliver anticancer drugs, 9-aminoacridine 
and camptothecin, and an interesting result was obtained. If 9-aminoacridine was adsorbed 
on the magnetic materials, its release from the surface in PBS buffer was promoted if the 
silica surface was not functionalized with organic moieties. If camptothecin was adsorbed on 
the same materials, the presence of phenylethyl functional groups inside the mesopores 
 vii
promoted the loading and delivery of the drug. The results were confirmed by in vitro drug 
delivery studies on Chinese hamster ovarian cells (CHO).  
We further applied the magnetic mesoporous silica nanomaterial to develop a 
magnetically active nanocarrier for photosensitive delivery of camptothecin to cancer cells. 
The mesopores were loaded with the drug and the pore entrances were blocked by 
functionalized cadmium-sulfide nanoparticles through an o-nitrobenzyl-based photolabile 
linker. Upon irradiation with UV light the photolabile linker was cleaved which induced 
release of the anticancer drug. The cooperative anticancer effect of capping CdS 
nanoparticles and loaded camptothecin was demonstrated by in vitro viability studies on 
CHO cells, upon exposure of the cell cultures to low power UV light. 
Finally, we constructed a mesoporous silica nanoparticle-based nanocarrier which 
was capable of delivering the mesopore-loaded molecules upon irradiation with visible light 
or upon the treatment with nitrogen-monoxide, histidine or imidazole, which are known 
intracellular molecules. Sulforhodamine 101 was used as a cargo molecule and it was 
entrapped inside the mercaptopropyl functionalized mesopores of MSN by mercapto-
coordinated Ru(bpy)2(PPh3)-moieties (bpy = 2,2’-bipyridine, PPh3 = triphenylphosphine). 
Upon exposure to visible light the Ru-S coordination bond is cleaved which allows release of 
the mesopore-loaded dye. Ligand substitution of the Ru-S coordination bond by nitrogen 
monoxide, imidazole and histidine was also shown to induce the release of cargo molecules, 
although with lower efficiency than with visible light. 
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CHAPTER 1. GENERAL INTRODUCTION 
 
Dissertation Organization 
 
This dissertation is divided into 6 chapters. The first chapter contains the general 
introduction of mesoporous silica nanoparticles, including the synthesis, mechanisms, 
modification methods and potential applications. Some of the recent reports on mesoporous 
silica nanoparticle-based functional supramolecular assemblies for targeted drug delivery are 
also included. Chapters 2 to 5 present journal papers on my research accomplishments for the 
past 6 years of my graduate studies, in chronological order. 
Chapter 2 describes functional UV light responsive delivery system for doxorubicin, a 
widely used anticancer drug. A positively charged drug molecules are adsorbed on 
organically modified surface of the MSN and the drug delivery principle is based on charge 
repulsion between UV light-generated, positively charged moieties on MSN surface and 
doxorubicin molecules. Release of the drug was also responsive to increase in acidity. My 
personal contribution represents 90 % of the presented research. 
Chapter 3 describes the development of magnetic analogues of mesoporous silica 
nanoparticles. A series of new materials was obtained with radial and hexagonal packing of 
the mesopores, containing magnetic nanoparticles inside the core of mesoporous silica 
framework. Loading and delivery capabilities of 9-aminoacridine (9AA) and camptothecin 
(CPT) from magnetic mesoporous silica nanoparticles (MMSN) are shown to be dependent 
on porous structure and presence of phenylethyl moiety inside the mesopores. 
Characterization of the magnetic drug delivery systems and in vitro viability studies on 
Chinese hamster ovarian (CHO) cells are presented. My personal contribution represents 
80 % of the presented research. 
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Chapter 4 presents the application of magnetic mesoporous silica nanoparticles for 
the construction of functional UV light sensitive drug carrier. Anticancer drug camptothecin 
was loaded inside the mesopores of the magnetic material and it was entrapped by 
functionalized cadmium-sulfide nanoparticles though a photolabile MSN-bonded linker. 
Release of the drug was triggered upon irradiation with UV light. Cooperative cytotoxic 
activity of capping CdS nanoparticles and loaded drug was observed upon the treatment of 
CHO cells and exposure to low power UV irradiation. My personal contribution represents 
80 % of the presented research. 
Chapter 5 describes encapsulation of sulforhodamine 101 as a cargo molecule inside 
the mercaptopropyl functionalized mesopores of MSN by mercapto-coordinated 
Ru(bpy)2(PPh3)-moieties (bpy = 2,2’-bipyridine, PPh3 = triphenylphosphine). Thus 
constructed nanocarrier was capable of delivering the mesopore-loaded molecules upon 
irradiation with visible light or upon the treatment with nitrogen-monoxide, histidine or 
imidazole. My personal contribution represents 90 % of the presented research. 
Chapter 6 is a general conclusion.  
 
Literature Overview 
 
Nanoscience, nanotechnology, nanomaterials and similar “nano”-words are word 
compounds developed only a few decades ago but the terms are very frequently used in 
recent years in and outside of scientific community. Among the nanoscopic materials, 
mesoporous silica nanoparticles (MSN) have attracted much attention 1-5 owing to their large 
surface area (up to 1000 m2/g), tunable pore diameter (2-30 nm), narrow pore size 
distribution, and high thermal stability. MSN material have been demonstrated as applicable 
for selective catalysis,6-10 drug delivery,2-5 sensing,11-14 and separation techniques.15-17 
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Mesoporous materials are classified as having a pore diameter between 2 and  
50 nm,18 based on International Union of Pure and Applied Chemistry (IUPAC) 
nomenclature. Microporous materials have pore diameter smaller then 2 nm while 
macroporous materials have pore diameter larger then 50 nm. MSN material is usually 
synthesized by hydrolysis and condensation of silica precursors (typically tetraethoxysilane) 
in alkaline or acidic environment in the presence of structure directing agents. These 
structure templating molecules are usually surfactants with hydrophilic headgroups and long 
hydrophobic organic tails (like cetyltrimethylammoniumbromide (CTAB)), which typically 
self-assemble in water into more complex structures.19 The tails of these amphiphilic 
molecules aggregate into hydrophobic domains while headgroups arrange on the phase 
separation interface, in contact with water molecules. Surfactants can adopt different 
structures in water environment (Figure 1), which mostly depends on their molecular 
structure, solution composition and concentration of the surfactant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Common aggregate structures (top row) and liquid crystalline phases (bottom row) of 
amphiphiles in water.19 
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Critical packing parameter (CPP) is a quantity which helps in predicting the expected 
structures of amphiphiles in water.20,21 The expression is CPP = ν/a0lc, where lc is the length 
and ν is the volume of space occupied by the hydrophobic tail of the amphiphile while a0 is 
the area of the headgroup. Small CPP (< 1/3) favors formation of structures with high surface 
curvature (for example micelles) while CPP in the range 1/3-1/2 favors tubular structures 
which are necessary for the formation of MSN type materials. Lamellar structure is favored if 
CPP value is around 1 while inverted hexagonal packing is achieved for CPP values higher 
then 1.  
All the surfactant self-assemble structures exist in solution and cannot be isolated 
without destroying the structure. However, addition of silica precursors affords formation of 
a layer of SiO2 polymer around micelle interfaces which stabilizes the assemblies.   
Mesoporous silica material with hexagonal porous structure was developed in 1992 
by scientists at Mobil corporation.1 The authors reported on a series of silicate and 
aluminosilicate mesoporous molecular sieves, designated as M41S.  One member of that 
series was MCM-41 material which contained hexagonal arrangement of mesopores. The 
authors also speculated on formation mechanisms of the material and two possible pathways 
are represented in Figure 2. Pathway (1) represents the scenario where surfactant first self-
assembles into hexagonal array of micellar rods, after which the silicate precursors serve to 
solidify the structure. In the pathway (2), silicate precursors play an active role in every step 
of assembly formation and help in achieving the final structure 
 
 
 
 
 
 
 
 
 
 
Figure 2. Possible mechanistic pathways for the formation of MCM-41: (1) liquid crystal phase initiated 
and (2) silicate anion initiated.  
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However, the as prepared MCM-41 material typically had non-uniform particle 
morphology as various shapes and particle diameters were obtained by the procedure. 
Subsequent modification of the preparation steps allowed construction of uniform, 
monodispersed nanoparticles. Particle morphology may be also influenced by addition of 
different organosilanes during the process of co-condensation of silica precursors  
(Figure 3).22 This co-condensation process allows direct functionalization of silica surface 
during the synthesis of the material, which was shown to be preferential for internal surface 
of the mesopores. Typically, organosilanes (R-TMS or R-TES, where R is organic functional 
group while TMS is trimethoxysilane and TES is triethoxysilane) is added into the reaction 
solution together with TEOS or immediately after the addition of TEOS, which affords 
incorporation of organosilanes in the final material. 
 
  
 
 
Figure 3. Organic functionalization of MSN by co-condensation 
 
Another technique for organic functionalization of silica surface is post-synthesis 
grafting. In this procedure non-functional MSN is first isolated and then condensed with 
added organosilane. Typically the grafting is done at elevated temperature (120 ºC) in water-
free solvents (toluene, DMF etc.). If MSN used for grafting still contains surfactant inside the 
mesopores, preferential functionalization of only external surface of MSN can be 
accomplished.  
After the preparation of MSN, surfactant molecules from the mesopores can be 
removed either by washing with acidified methanol solution or by calcination. The difference 
between materials isolated by the two procedures is that after washing procedure the material 
still contains most of its surface silanol groups. Calcination at high temperature (usually  
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550 ºC) removes those silanol moieties along with any present organic molecules. However, 
silanol groups of the calcined material can be recovered by boiling in water.  
In terms of drug delivery application, MSN offers many beneficial characteristics for 
the construction of an efficient drug delivery system (DDS). We have shown in vitro that 
MSN is biocompatible material up to a concentration of 100 μmol/g.23 Recent report also 
showed that non-functionalized MSN was biocompatible in mice for internalization by 
intraperitoneal injection up to a concentration of 1 mg/ml and if subcutaneous injection was 
used up to ~ 30 mg/ml.24  
Diameter of MSN nanoparticles is typically 100-200 nm which allows them to 
penetrate the cell membrane and enter the cell cytoplasm by the process of endocytosis.25 In 
addition, the size of MSN enables selective accumulation of a MSN based DDS in the 
extracellular medium of tumor tissue due to enhanced permeability and retention effect 
(EPR) of cancerous tissue.26 This effect in cancer tissue occurs due to formation of additional 
vasculature system through angiogenesis because of increased need for nutrients. Namely, 
once the cluster of tumor cells reaches the size of about 2 mm the angiogenesis must be 
activated in order to sustain the growth of the tumor tissue. These newly formed blood 
vessels are typically highly permeable and do not have functional lymphatic drainage system 
which enables the selective accumulation of macromolecules.   
Additional DDS-beneficial characteristic of MSN is its high surface area, which is 
typically around 1000 m2/g. This feature allows high loading of the therapeutic agents on the 
surface of MSN. The drug can be adsorbed on the silica surface typically through 
electrostatic interactions, van der Waals forces or/and through forming hydrogen bonds with 
the surface silanols. In addition, surface of MSN can be easily functionalized by 
condensation reaction with desired organosilanes, which allows construction of more 
complex drug delivery systems. 
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Hence, MSN offers the possibility of construction of functional supramolecular 
assemblies. Drug molecules can be filled inside the mesopores of MSN and entrapped by 
capping the pore entrances with suitable blockers. Up to now there have been reports on 
application of CdS,27 Au,28 Fe3O4 nanoparticles,29 rotaxanes,30 dendrimers,31 polymers11 and 
proteins32 as capping moieties while triggering the release of entrapped molecules was 
accomplished by chemical agents,27,30 enzymes,32 temperature change,33 light irradiation34 or 
change in pH value.35 For example, we demonstrated encapsulation of molecules inside the 
mesopores of MSN by covalently bonded CdS nanoparticles (Figure 4).27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic representation of the CdS nanoparticle-capped MSN-based drug delivery system.27 
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The controlled-release of the drug molecules was achieved upon chemical reduction 
of the disulfide linkage between the CdS nanoparticles and the MSN. In the case of using 
magnetite nanoparticles as caps for the MSN mesopores,29 the whole system was shown to be 
magnetically active, which showcased the possibility of controlling the location of drug 
release with external magnetic field, i.e., magnetically targeted drug delivery. Another recent 
report from our group demonstrated the use of MSN based DDS for the stimuli responsive 
delivery of both bioactive caps and cargo molecules.36 Namely, saccharide responsive, 
insulin capped MSN was used to deliver gluconic acid-modified insulin (G-Ins) and the 
encapsulated drug (cyclic adenosine monophosphate (cAMP)), both of which can be used in 
diabetes treatment (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. (a) Schematic representation of the glucose-responsive MSN based delivery system for 
controlled release of bioactive G-Ins and cAMP. Transmission electron micrographs of (b) boronic acid-
functionalized MSN and (c) FITC-G-Ins-capped MSN.36 
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MSN based molecular valve for the entrapment and delivery of cargo molecules was 
also devised by a combined effort from Stoddart and Zink research groups.30,37 The authors 
reported on a rotaxane functionalized MSN which reversible entraps and releases small 
molecules from the mesopores (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Graphical representations of the surface attachment of bistable rotaxanes to silica particles 
along with a cycle for loading and release of guest molecules. (a) The structural formula of the bistable 
[2]rotaxane R4+ and the procedure used for tethering R4+ to the surface of mesoporous silica particles. (b) 
The proposed mechanism for the operation of the nanovalve. The moving part of the molecular valve is a 
CBPQT4+ ring (blue), which shuttles between a TTF station (green) and a DNP station (red) under redox 
control. The openings of the cylindrical pores on the silica are blocked by the CBPQT4+ ring when the 
valve is closed. Guest molecules (turquoise spheres) are loaded in Step 1 by diffusion into the open pores 
when the CBPQT4+ ring is located on the TTF station. The valve is closed in Step 2 by oxidation of the 
TTF unit to its dication, causing the CBPQT4+ ring to move to the DNP station, which is much closer to 
the openings of the pores. The valve can be opened (Step 3) by adding ascorbic acid to reduce the TTF 
dication back to its neutral state, whereupon the CBPQT4+ ring moves back from the DNP station to be 
relocated around the much more π electron-rich TTF station, releasing the guest molecules in Step 4. The 
valve is ready for recharging (i.e., returning to Step 1). Thus, the valve can be closed and opened 
reversibly. The silica particles are not drawn to scale, and only a few of the ordered pores are shown. 30 
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Schlossbauer et al. recently demonstrated utilization of nature’s host-guest chemistry 
for capping the mesopores of MSN.32 Namely, tetrameric protein avidin was used as a cap 
for entrapping molecules inside the mesopores of biotin functionalized MSN. Furthermore, 
release of the cargo molecules was achieved by exposure to a solution of proteolytic enzyme 
which disintegrates the protein cap.    
Targeting specific cells and organs within the body can also be accomplished by 
modification of a surface of DDS with antibodies or appropriate ligands.38 For example, 
Rosenholm et al recently reported targeting of cancer cells by folic acid (FA) functionalized 
MSN.39 The authors first functionalized the surface of MSN with a layer of 
polyethyleneimine (PEI) onto which they attached folic acid molecules. PEI layer in this case 
had a role in multiplying possible FA attachment sites as well as in increasing the suspension 
stability of the DDS and improving its cell uptake ability.40 The results showed that the 
cancer cells internalized an order of magnitude more of FA functionalized MSN compared to 
the healthy cells. In addition, endocytosis of the DDS was successfully inhibited by the 
addition of free folic acid. This cancer targeting effect was possible due to overexpression of 
folate receptors on the surface of cancer cells.41 
Other possible pathways exist for the development of cancer homing nanodevices. 
For example it has been shown that if anticancer drug doxorubicin was attached to a 
tripeptide sequence Arg-Gly-Asp (RGD), αv integrins are selectively targeted, which are 
overexpressed on the angiogenic vessels of solid tumors.42 This type of cancer targeting 
which is based on interaction with specific receptors of tumor tissue or based on its EPR 
effect can be considered as passive cancer targeting. That is, drug-carrier system is 
intravenously introduced into the organism and its spontaneous accumulation at the cancer 
site is expected. However, even with the higher affinity for tumor tissue, much of the 
cytotoxic drugs still end up in healthy cells.  
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Alternatively (or in addition to some forms of passive targeting), the site of drug 
delivery can be actively targeted by an external stimulus, which is a topic of this dissertation. 
For example, the drug carriers can be magnetically active which would open the possibility 
to control the location of a DDS by an externally applied magnetic force.43 Additionally, 
release of the drug from DDS can be actively controlled by an external stimulus, for instance 
by light irradiation.  
This dissertation will cover design and development of novel nanodevices for UV 
light (chapters 2 and 4) and visible light (chapter 5) responsive drug delivery. In addition, 
development of magnetic analogues of mesoporous silica nanoparticles (MMSN) for drug 
delivery is described in chapter 3. We envision that these results can be used to improve the 
efficacy of cancer treatment and reduce the harmful effects of anticancer drugs on healthy 
tissue.  
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Abstract 
 
Anticancer drug doxorubicin (Dox) was adsorbed on nitroveratryl carbamate-
protected aminopropyl-functionalized mesoporous silica nanoparticles (MSN). Upon 
exposure to UV light positively charged propylammonium moieties were formed on MSN 
surface which caused expulsion of positively charged doxorubicin molecules from the 
surface of nanoparticles. Light induced release of the drug was a faster process then its 
photodegradation which yielded a net effect of photosensitive Dox release. The drug release 
was also increased with lowering pH value from 7.4 to 6.4. We believe that these results may 
be beneficial for targeting the doxorubicin delivery selectively to tumor cell clusters by 
externally applied light irradiation, which would work in cooperation with targeting weakly 
acidic extracellular matrix of tumor tissues.  
 
Introduction 
  
Ever since its discovery and first antitumor tests in 1969,[1] Doxorubicin (Dox) has 
been one of the most used anticancer drugs in chemotherapy. Even though it was shown 
effective against wide range of tumors,[2] the severe adverse effects that Dox induces on 
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healthy tissue are still problems that are preventing its more effective use.[3] The same issue 
exists with implementation of other cytotoxic drugs and it brought a need for development of 
targeting drug delivery systems (DDS), which would account for administration of cytotoxic 
drugs specifically to the cancer cells.[4]  
Much of the efforts have been concentrated on devising the DDS based on 
mesoporous silica nanoparticles (MSN).[5] Their solid silica framework ensures the 
structural integrity of DDS but at the same time allows easy manipulation of its chemical 
characteristics by condensation reaction with various organosilanes to form a surface layer of 
organic functional groups. In addition, MSN offers high surface area, isostructural 
mesoporosity and a particle diameter (100 - 200 nm) which is in range to enhance the 
targeting ability of a DDS due to enhanced permeability and retention (EPR) effect of 
cancerous tissue.[6]  
Light responsive DDS have been recently investigated and it was shown to be a 
promising route toward establishing functional targeted drug delivery.[7] However, light 
responsive Dox delivery is a challenge because the drug have been found to undergo 
degradation upon exposure to light.[8] The process is manifested by decrease in drug 
fluorescence due to destruction of the chromophore. First order kinetics was determined for 
the process, it is inversely proportional to Dox concentration and the degradation increases 
with pH value of the solution. Additionally, release of drugs upon lowering pH value is a 
desirable feature of drug delivery systems because most solid tumors have lower extracellular 
pH compared to the surrounding healthy tissue.[9] Hence, we set a goal to construct a 
doxorubicin delivery system responsive to both a decrease in pH value and light irradiation. 
For that function we devised a MSN functionalized with propyl-carbamic acid 4,5-
dimethoxy-2-nitrobenzyl ester (or nitroveratryl-carbamate protected aminopropyl 
functionalized mesoporous silica nanoparticles = NVCAP-MSN). Nitroveratryl (NV) moiety 
have been known for several decades as an effective photoresponsive protection group.[11] 
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Scheme 1a depicts the organic functional groups attached on the silica surface and their 
photochemically induced degradation pathway. Irradiation of the suspension of the material 
in PBS buffer with UV light (350 nm) triggers the degradation of carbamate linkage, 
followed by the release of 4,5-dimethoxy-2-nitroso-benzaldehyde, CO2 and free amine 
groups. We propose that if doxorubicin (Scheme 1b) was adsorbed on the silica surface of 
NVCAP-MSN, its delivery to the surrounding medium upon irradiation of the material would 
be induced by electrostatic repulsion between freed surface-bound propylammonium 
moieties and positively charged amine group from doxorubicin. 
 
 
 
 
 
 
 
 
 
 
Scheme 1. a) Structural representation of NVCAP-MSN and UV light triggered deprotection of amine 
groups; b) molecular structure of doxorubicin. 
 
Experimental Section 
 
Tetraethoxyorthosilicate (TEOS), n-Cetyltrimethylammoniumbromide (CTAB),  
3-aminopropyltrimethoxysilane (AP-TMS), 1,1’-carbonyldiimidazole and  
4,5-dimethoxy-2-nitrobenzyl alcohol were commercially available (Aldrich) and were used 
as received. 
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Instrumental Methods, Conditions and Parameters for Structural Characterization: 
Powder XRD diffraction data were collected on a Scintag XRD 2000 X-ray 
diffractometer using Cu (Kα) radiation. Nitrogen adsorption and desorption isotherms, 
surface areas, and median pore diameters were measured using a Micromeritics Tristar 3000 
surface area and porosity analyzer. Sample preparation included degassing at 100 °C for 5 h. 
Specific surface areas and pore size distributions were calculated using the Brunauer-
Emmett-Teller (BET) and Barrett-Joyner-Halenda (BJH) method, respectively. Particle 
morphology of the material was determined by scanning electron microscopy (SEM) using a 
JEOL 840A scanning electron microscope. IR spectra were recorded by using Nicolet Nexus 
470 FT-IR. Solid-state 29Si and 13C CP-MAS NMR spectra were obtained on Bruker 
AVANCE-600 NMR spectrometer. Fluorescence measurements were performed on Horiba 
group Fluoromax-2 fluorometer. 
 
Synthesis of double-functionalized aminopropyl-MSN material (AP2-MSN):  
n-Cetyltrimethylammoniumbromide (CTAB, 1.00 g, 2.74 x 10-3 mol) was first 
dissolved in 480 mL of Nanopure water. NaOH(aq) (2.00 M, 3.50 mL) was added to CTAB 
solution, followed by adjusting the solution temperature to 353 K. TEOS (5.00 mL, 2.57 x 
10-2 mol) was first introduced dropwise to the surfactant solution, followed by the dropwise 
addition of a freshly prepared solution of APTMS (0.9 mL, 5.13 x 10-3 mol) in 9.1 ml of 
water. The mixture was allowed to stir for 2 h to give rise to white precipitate (as synthesized 
AP-MSN). The solid product was filtered, washed with deionized water and methanol, and 
dried for 12 h under high vacuum and 353 K in order to stabilize the mesoporous structure. 
Additional grafting of APTMS on the external surface of AP-MSN was performed by 
refluxing APTMS (353 μl, 2 x 10-3 mol) with the suspension of as synthesized AP-MSN  
(1 g) in dry toluene (50 ml). After filtering and washing with toluene, 2-propanol and 
methanol, the as synthesized AP2-MSN was again dried under high vacuum at 353 K. Final 
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double-functionalized aminopropyl-MSN material was obtained upon removal of the CTAB 
surfactant template by Soxhlet extraction with a solution of HCl in methanol (1%, v:v). After 
24 h of extraction the material was additionally washed with deionized water and methanol, 
and it was again placed under high vacuum at 353 K to remove the remaining solvent from 
the mesopores. 
 
Preparation of 2-nitroveratrylcarbamate-aminopropyl-MSN (NVCAP-MSN): 
The following procedure was done under nitrogen atmosphere. Solution of  
1,1’-carbonyldiimidazole (324.4 mg, 2 x 10-3 mol) in 4 ml of dry dichloromethane was 
cooled in an ice-water bath to 273 K. Solution of 4,5-dimethoxy-2-nitrobenzyl alcohol  
(426.4 mg, 2 x 10-3 mol) in 23 ml of dry dichloromethane was separately prepared and added 
drop-wise to the stirred solution of 1,1’-carbonyldiimidazole. The solution was protected 
from light and then stirred for additional 1 h at room temperature after which 500 mg of dry 
AP2-TMS was added. The suspension was stirred for additional 48 h in order to form the 
carbamate linkage. Prepared NVCAP-MSN material was filtered, washed with plenty of 
dichloromethane, methanol, water and finally again with methanol and dried in a lyophilizer. 
In order to determine the amount of nitroveratryl groups on the surface of MSN, the filtrate 
was collected and solvents evaporated. The residue was dissolved in PBS buffer (10 mM,  
pH = 7.4, I = 154 mM) which now contained free 2-nitroveratryl alcohol, imidazole and 
carbonates, due to degradation of any intermediate imidazolide derivative in water 
environment. UV-VIS spectrum of the solution was taken and the amount of nitroveratryl 
groups on the surface of MSN (1.2 mmol of NV groups/g AP2-MSN) was determined from 
the difference between the starting amount of nitroveratryl alcohol and the amount 
determined by measuring absorbance of nitroveratryl alcohol from the filtrate at 350 nm, 
quantified from a standard curve. 
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Adsorption of doxorubicin on the surface of NVCAP-MSN (Dox@NVCAP-MSN): 
Doxorubicin hydrochloride (5.8 mg, 1 x 10-5 mol) was dissolved in 3 ml of methanol 
and neutralized with NaOH solution in methanol. NVCAP-MSN (100 mg) was added to the 
solution and the suspension was protected from light and stirred at room temperature for 24 
h. The as prepared Dox@NVCAP-MSN was filtered and washed with plenty of methanol. 
The amount of adsorbed drug (80 mg of Dox/g of NVCAP-MSN) was determined from the 
difference between the starting amount of doxorubicin and the amount determined by 
measuring absorbance of the drug from the filtrate at 490 nm in PBS solution, quantified 
from a standard curve. 
Irradiation of the samples was performed on Rayonet RPR-100 photoreactor 
equipped with 16 RPR-3500 lamps. The lamps have an emission maximum at 350 nm. Light 
intensity of the irradiation source was measured with Spectroline DSE-2000HA/L 
Radiometer/Photometer. At the center of the photoreactor the measured light intensity was 
5.5 mW/cm2. Prepared materials were subjected to irradiation by placing them in the center 
of the photoreactor as PBS suspensions (1 mg/ml). During irradiation the samples were 
stirred with magnetic stirrer and light induced heating was prevented by cooling with an 
integrated fan. 
For the first experiment release of the drug was measured in PBS buffer at two pH 
values (6.4 and 7.4). Suspension of the material (1 mg/ml) was first stirred in dark for 20 h 
and fluorescence of doxorubicin was measured at 595 nm (exc. 495 nm) from the PBS 
supernatant after centrifugation at designated times  The samples were then placed in a 
photoreactor and subjected to irradiation for 30 minutes under stirring. After that, 
fluorescence of the supernatant was again measured as described and the suspensions were 
returned to stirring in dark as the measurements continued.    
Second release experiment was done in PBS buffer at pH = 7.4. Suspension of the 
material (1 mg/ml) was first stirred in dark for 5 h until no additional release of Dox was 
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observed. The sample was then placed in photoreactor and subjected to irradiation. At 
designated times the suspension was centrifuged, fluorescence of doxorubicin was measured 
and the samples were immediately returned to the photoreactor for additional irradiation. 
Amount of the released drug was determined from a previously prepared standard curve. 
 
Results and Discussion 
 
Preparation of the material included synthesis of aminopropyl-functionalized MSN by 
our established co-condensation procedure.[3c,d] In order to increase the surface coverage of 
organic functionality as synthesized material was additionally grafted with aminopropyl-
trimethoxysilane, followed by surfactant extraction with diluted solution of HCl in methanol. 
Formation of nitroveratryl carbamate was accomplished by following the procedure reported 
by D’Addona and Bochet.[12] Namely, NV alcohol and 1,1’-carbonyldiimidazole were 
initially coupled in dry dichloromethane solution, after which the as made imidazolide 
derivative was reacted with primary amine groups from the MSN surface. The amount of 
nitroveratryl groups on the surface of MSN was determined after the reaction to be 1.2 
mmol/g NVCAP-MSN, by measuring UV-VIS absorbance of NV alcohol from PBS solution 
of the filtrate residue.   
SEM image of NVCAP-MSN (Figure 1a) reveals the spherical morphology of the 
material with average diameter of 184 ± 44 nm. XRD analysis of NVCAP-MSN (Figure 1b) 
showed the presence of a single diffraction peak, attributed to [100] reflection from 
hexagonally packed mesopores. Higher order reflections ([110] and [200]) which are often 
seen on MSN type materials are missing in this case due to disruption of longer range 
symmetry after the grafting procedure and carbamate formation.  
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Figure 1. a) Scanning electron micrograph (SEM) image and b) small angle powder X-ray diffractogram 
(XRD) of NVCAP-MSN. 
 
The presence of nitroveratryl carbamate protection groups was confirmed by 13C 
CPMAS NMR spectrum (Figure 2) and IR spectrum (Table 1, Figures 3 and S1). 
 
 
 
 
 
 
 
 
 
 
Figure 2. 13C CPMAS NMR spectrum of NVCAP-MSN and peak assignment 
 
In order to test the reactivity of NVCAP-MSN and capability to produce the free 
amine moieties, material suspension was subjected to UV irradiation for 30 minutes (350 nm, 
5.5 mW/cm2). After extensive washings and drying, IR spectrum of the produced material 
was taken and the result is shown on Figure 3. As can be seen, the irradiation caused 
 21
0
0.1
0.2
0.3
1200130014001500160017001800
Wavenumber (cm-1)
A
bs
or
ba
nc
e 
NVCAP-MSN
30 min irradiation
AP-MSN
emergence of a new broad band at 1640 cm-1, which can be assigned to δ(NH3+) of a newly 
freed aminopropyl moieties. As a comparison, the same vibration band was observed in IR 
spectrum of aminopropyl-functionalized MSN, before the coupling to nitroveratryl alcohol.  
In addition, release of 4,5-dimethoxy-2-nitroso-benzaldehyde from the material upon 
irradiation in PBS was clearly evident by the appearance of intense UV-VIS band, centred at 
350 nm (Figure S2). 
Zeta potential measurements in PBS buffer at pH = 7.4 revealed that before 
irradiation NVCAP-MSN showed the value of + 5.7 mV. The value is positive probably 
because of some free aminopropyl moieties that were left without carbamate protection even 
after 48 h of coupling reaction. After 5 minutes of irradiation the ζ potential value increased 
to + 10.3 mV, which is in agreement with the release of positively charged amine moieties. 
 
 
 
 
 
 
 
 
Figure 3. Comparison of IR spectra of NVCAP-MSN (top), NVCAP-MSN after 30 minutes of irradiation 
(middle) and aminopropyl-functionalized MSN (bottom) 
 
Table 1. Assignment of the bands from IR spectrum of NVCAP-MSN 
Wavenumber 
(cm-1) 1700 1584 1524 1333 1280 
Assignment C=O st 
N-H 
δ 
NO2 
st as 
NO2 
st sy 
N-CO-O  
st as 
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To study capability of NVCAP-MSN to adsorb and deliver doxorubicin upon 
exposure to UV light, the material was protected from light and stirred in a methanol solution 
of the drug. After allowing 24 h for adsorption, doxorubicin loaded material (Dox@NVCAP-
MSN) was washed with plenty of methanol and dried. The amount of adsorbed drug was  
80 μmol/g NVCAP-MSN, as determined from the UV-VIS absorption of doxorubicin from 
the filtrate solution. BET surface area (Figure S3) of the resulting Dox@NVCAP-MSN 
showed the value of 458 m2/g, which is a decrease from 564 m2/g as obtained for NVCAP-
MSN due to surface adsorption of the drug. 
Release of doxorubicin from the material was measured in PBS buffer at two pH 
values (6.4 and 7.4) and the response upon 30 minutes of irradiation with UV light is 
represented in Figure 4a. It is evident that the release of doxorubicin is responsive both to pH 
value and UV irradiation. Solvation of Dox@NVCAP-MSN in PBS induces initial release of 
the drug as a result of electrostatic repulsion between now positively charged Dox molecules 
and MSN surface. Higher amount of doxorubicin was released at pH = 6.4 because more of 
the drug senses electrostatic repulsion from the positively charged solid surface. Namely 
amine group from doxorubicin is partially deprotonated at pH 7.4 (pKa = 8.22)[13] while 
fully protonated at pH 6.4. In addition, NCAP-MSN has a higher total positive charge at pH 
6.4 because of presence of surface silanol groups (pKa = 6.8) which are deprotonated at pH 
7.4, decreasing the total positive charge of the surface. Presence of the silanol groups was 
confirmed by 29Si NMR DP MAS spectrum of NVCAP-MSN (Figure S4). After irradiation 
of the sample for 30 minutes doxorubicin fluorescence increased, which indicated successful 
expulsion of Dox molecules because of repulsion with freed propylammonium ions from the 
surface. Amount of the drug in solution increased even though employed irradiation 
conditions cause photodegradation of doxorubicin as well, as tested for the solution of Dox 
(1 μM) in PBS at pH 7.4 (Figure S5). We can consider that UV irradiation of Dox@NVCAP-
MSN has both direct effects: cleavage of carbamate linkage and photodegradation of 
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doxorubicin. However, the photocleavage of carbamate linkage seems to be a faster process 
under these conditions, which yields in a net release of the drug from its nanocarrier. As 
stated above, photodegradation of doxorubicin is known to be inversely proportional to its 
concentration. Hence, we believe that since doxorubicin molecules are in this case adsorbed 
on the surface of nanospheres, their photodegradation is reduced due to high local 
concentration of drug molecules on the surface of nanoparticles. Bandak et. al. already 
reported that encapsulation of doxorubicin inside polyethyleneglycol-coated liposomes 
reduced UV-induced degradation of the drug.[10] This result was ascribed to high local 
concentration of doxorubicin, in addition to low pH value inside the liposomes. Once the 
drug molecules are released from the surface they are susceptible to faster photodegradation. 
However, degraded molecules are continuously outnumbered by the newly released 
molecules from the surface, which effects in net release of the drug.  
In order to demonstrate the ability of the DDS to deliver Dox upon prolonged 
irradiation conditions, we subjected suspension of the drug loaded material to consecutive 
treatments with UV irradiation (Figure 4b). Continuous release of doxorubicin was 
successfully achieved which was proportional to the period of UV irradiation.  
From the Figure 4a we can also notice that initial increase of doxorubicin 
concentration was more then 2 times higher at pH 6.4 when compared to the photoresponse 
at pH 7.4. In addition to better repulsion between the drug and host MSN at lower pH, as 
discussed above, the reasons for this result can be partially attributed also to slower 
photodegradation of released Dox molecules and faster deprotection of NV groups at lower 
pH value.[11c] However, after the initial rise in released drug amount, emission of 
doxorubicin deteriorates for up to 2 hours after irradiation stopped.  
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Figure 4. Release of doxorubicin from Dox@NVCAP-MSN: a) in PBS buffer at pH = 6.4 and pH = 7.4. 
Suspensions were subjected to 30 minutes of irradiation with UV light (350 nm) starting from the points 
marked by arrows; b) Amount of the released drug as a function of irradiation time in PBS buffer at  
pH = 7.4 compared to non-irradiated sample (dark). The progress was monitored after the initial 
solvation induced jump in released drug. 
 
This effect is not due to continued degradation of the drug in dark. We tested if the 
same effect would be observed on a solution of doxorubicin (2 mg/ml) in PBS buffer for both 
pH values (6.4 and 7.4).  After 30 minutes of irradiation of Dox solution in PBS, the 
emission intensity decreased when compared to the starting intensity but no further change 
was noticed after turning off the UV irradiation source. The same reduction of Dox 
fluorescence was noticed if we did the release experiment in MOPS buffer as well as in 
water, which indicates that the effect does not happen because of eventual buffering of 
positive charges of propylammonium ions through specific coupling with anions from buffer 
solution. We determined that this effect occurs as a result of partial backreaction of 
photoproducts, i.e. free MSN-attached amines react with 4,5-dimethoxy-2-nitroso-
benzaldehyde to form imine derivative (4,5-dimethoxy-2-nitroso-benzylidene)-propylamine-
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MSN) on the surface of MSN. Since imine moiety is not charged at the employed conditions, 
a part of released doxorubicin was able to readsorb on MSN surface. It is possible as well 
that doxorubicin couples with released benzaldehyde moiety and forms imine derivative in 
the same manner, which would have similar outcome as imine derivatized Dox would not be 
charged and would adsorb freely on the surface. This explanation is supported by the fact that 
doxorubicin concentration decreases more after irradiation at lower pH because imine 
formation is acid catalyzed process.  
The same behavior of photoproducts after deprotection of NV-protected amines is 
known since 1970, when Patchornik et. al. reported their findings.[11a] The authors were 
also able to prevent imine formation by addition of semicarbazide and other competing 
nucleophiles. Hence, we tested the release of doxorubicin in the presence of 5 mM 
semicarbazide in PBS and as a result no deterioration of Dox fluorescence intensity was 
noticed after the irradiation stopped (Figure 5). 
 
 
 
 
 
 
 
Figure 5. Comparison of the release of doxorubicin monitored as fluorescence emission at 595 nm  
(exc. 495 nm) of supernatant solution in 10 mM PBS (pH 6.4) and in the 10 mM PBS (pH 6.4)  
solution containing 5 mM semicarbazide. PBS + SC solution was irradiated with UV  
light for 30 min starting with the point marked by arrow.  
 
Even though we used continuous UV irradiation to release the drug which also caused 
its photodegradation, we believe that this DDS can be more effectively applied for targeted 
doxorubicin delivery if e.g. ultrafast laser pulses are used for triggering the drug release. We 
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envision that such intense ultrashort laser pulse may effectively target cancerous tissue and 
induce intracellular release of dox molecules while photodegradation of the drug would be 
minimized because of its high local concentration on the silica surface. Such implementation 
is yet to be demonstrated.  
 
Conclusion 
 
We developed a doxorubicin delivery system responsive to UV light irradiation and 
increase in acidity. The anticancer drug was adsorbed on nitroveratryl carbamate-protected 
aminopropyl-functionalized mesoporous silica nanoparticles. Upon exposure to UV light 
positively charged propylammonium moieties were formed on the surface which yielded 
desorption of positively charged doxorubicin molecules from the surface of nanoparticles. 
Photosensitive release of the drug was a faster process then its photodegradation, which 
yielded in a net increase of dox concentration in PBS solution, as a direct response to UV 
irradiation. The amount of released doxorubicin was proportional to irradiation time and 
higher amount of the drug was released at weakly acidic conditions when compared to drug 
release at physiological pH. We believe that these results may open the possibilities for 
cooperative light and pH responsive selective targeting of doxorubicin delivery to cancerous 
tissue. 
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Appendix A 
 
 
 
 
 
 
 
 
Figure S1. IR spetrum of NVCAP-MSN 
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Figure S2. Change in UV-VIS absorbance upon 30 minutes of irradiation with UV light (350 nm) of 
supernatants obtained after centrifugation of a suspension of NVCAP-MSN in PBS before  
(bottom curve) and after irradiation (top curve)  
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Figure S3. a) BET nitrogen adsorption/desorption isotherms and b) BJH average pore diameter 
distribution for NVCAP-MSN and Dx@NVCAP-MSN 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. 29Si NMR DP MAS spectrum of NVCAP-MSN 
 
Various Si environments are designated as follows: Q3=(≡SiO)3SiOH, Q4=(≡SiO)4Si, T2=(≡SiO)2Si(OH)R, 
T3=(≡SiO)3SiR, where R is an organic functional group. 
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Appendix C 
 
 
Figure S5. Photodegradation of PBS solution (pH = 7.4) of doxorubicin as a function of irradiation time. 
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Abstract 
 
A series of core-shell, iron-oxide nanoparticle embedded magnetic mesoporous silica 
nanoparticle materials with radial (MMSN-r) and hexagonal (MMSN-h) porous structures are 
synthesized via a facile synthetic method.  The MMSN materials are loaded with anticancer 
drugs, 9-aminoacridine (9AA) and camptothecin (CPT) and controlled release profiles of the 
drugs from these materials are investigated as a function of porous structure and presence of 
phenylethyl functionality. Completely opposite behavior of the adsorbed drugs is observed in 
terms of the release from phenylethyl-functionalized pores of MMSN (Ph-MMSN) and non-
functionalized material. While large release of 9AA is observed in case of non-functionalized 
MMSN, the loading and release of camptothecin is promoted by the presence of phenylethyl 
functionality. Controlled release properties of drug loaded magnetic materials were 
confirmed by viability studies on Chinese hamster ovarian (CHO) cells, which revealed 
efficient cytotoxic activity of CPT loaded Ph-MMSN-h and 9AA loaded MMSN-h material. 
In addition, we demonstrated the ability of externally applied magnetic field induced 
agitation to promote the release of anticancer drug from magnetic material. We envision that 
the MMSN materials could serve as a new generation of drug delivery carriers with an 
externally controlled site-targeting ability and capability to modify the drug release 
properties of the drug delivery system by the force externally applied magnetic field. 
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Introduction 
 
The synthesis of structurally ordered mesoporous silica materials with various pore 
arrangement and particle morphologies have been extensively studied during the recent 
years.1-5 Owing to the large surface area (> 700 m2 g-1), tunable pore diameter (2-30 nm), 
narrow pore size distribution and high thermal stability, mesoporous silica nanoparticles 
(MSN) were successfully applied for selective catalysis,6-10 drug delivery,[2-5] sensing,11-14 
and separation.15-17 Diameter of MSN spheres is usually in range 100-200 nm which is very 
suitable for use as drug delivery vehicles in anticancer therapy due to enhanced permeability 
and retention effect (EPR) of cancerous tissue.18 This effect enables spontaneous 
accumulation of drug carriers along with any other macromolecules of suitable size in the 
extracellular medium of tumor tissue. The nanoparticles are then readily endocytosed by 
tumor cells as we already reported for mesoporous silica nanoparticles.19,20 We also 
demonstrated that in vitro biocompatibility of MSN material is fairly high (up to a dosage of 
100 μg ml-1) and that hemolysis of red blood cells by MSN is much lower then reported for 
amorphous silica,21 which may open the possibilities for pharmacological applications. In 
other studies we reported that mesopores of MSN could be efficiently loaded with drug 
molecules and their retention ensured by trapping them inside the pores with different “caps”, 
such as CdS and Fe3O4 nanoparticles.22,23 The caps were covalently bonded to the MSN via 
chemically cleavable disulfide linkage and triggering of the drug release was achieved by 
intracellular disulfide reducing agents.  In the case of using magnetite nanoparticles as caps, 
the whole system was shown to be magnetically active, which showcased the possibility of 
controlling the location of drug release with external magnetic field, i.e., magnetically 
targeted drug delivery. There has been a growing research interest lately in designing MSN 
type of mesoporous materials that are intrinsically magnetic, aiming for imaging and delivery 
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applications.24-31 For example, magnetic iron oxide nanoparticles were successfully grafted 
onto the external surface of MCM-41 type of mesoporous silica particles.24 Also, mesoporous 
silica frameworks were recently coated on magnetic metal oxide nanoparticles and yielded 
different core-shell MSN materials.32-34  
To achieve the goal of using magnetic mesoporous nanomaterials for various drug 
delivery, separation, catalysis, and sensor applications, an important prerequisite would be to 
gain the understanding of the release ability of guest molecules from mesoporous framework 
of the host material. This process can be influenced by the different structural parameters of 
the mesoporous material.35 The silica framework can be functionalized with various organic 
groups and the materials can adopt different porous structure, both of which may have an 
influence on loading and releasing molecules from the host material.  
Herein, we report on the synthesis and characterization of a series of core-shell, iron-
oxide nanoparticle embedded, magnetic mesoporous silica nanoparticles (MMSN) with radial 
(MMSN-r) or hexagonal porous structures (MMSN-h).  As detailed below, we developed a 
facile synthetic method that allows tuning of the pore orientations of MMSN materials. The 
MMSN materials were loaded with anticancer drugs, 9-aminoacridine (9AA) and 
camptothecin (CPT) (Scheme 1) and release kinetics of the drugs were monitored while 
controlling the location of the material by externally applied magnetic field. Release profiles 
of the drugs were determined as a function of different porous structure as well as presence 
of phenylethyl functionalization. Controlled release properties of drug loaded materials were 
also investigated by cell viability study on Chinese hamster ovarian cells (CHO).  
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Scheme 1. Molecular structures of camptothecin (a) and 9-aminoacridine (b) 
 
Camptothecin and its derivatives have shown remarkable activity against wide range 
of cancers36-40 while 9AA and derivatives are known as mutagens,41,42 antiseptics and 
anticancer drugs.43,44 In addition to cancerous cells, anticancer drugs are known to be very 
toxic to healthy tissue.  This is the reason a method for selective drug delivery to cancer cells 
is needed. Camptothecin would additionally benefit from an efficient delivery vector due to 
its hydrophobicity and low solubility in physiological environment. Hence, we focused on 
developing MMSN into drug delivery vehicles which would then have a possibility of 
applying external nondestructive force, such as magnetic field, to control the location of the 
delivery systems and possibly even manipulate the drug release process. Magnetic field-
induced control of the location of drug treatment has been shown already to yield a 
significant improvement in the efficiency and selectivity of the treatment by a drug released 
from magnetic carriers.45 For a final study of this report we monitored the release of 9AA 
from MMSN materials under the influence of agitated magnetic field. This facile method 
(a) 
(b) 
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may be proven an effective tool for manipulation of a drug release from magnetic drug 
delivery systems. 
 
Experimental Section 
 
Instrumental Methods  
Powder XRD diffraction data were collected on a Scintag XRD 2000 X-ray 
diffractometer using Cu Kα radiation. Nitrogen adsorption and desorption isotherms, surface 
area and median pore diameter were measured using a Micromeritics ASAP2000 
sorptometer. Sample preparation included degassing at 100 °C for 6 h. Specific surface areas 
and pore size distributions were calculated using the Brunauer-Emmett-Teller (BET) and 
Barrett-Joyner-Halenda (BJH) method, respectively. Particle morphology of these materials 
was determined by scanning electron microscopy (SEM) using a JEOL 840A scanning 
electron microscope. TEM examination with energy dispersive X-ray analysis (EDX) was 
completed on a Tecnai G2 F20 electron microscope operated at  
200 kV. Thermogravimetric measurements, TGA and DTA-TGA were obtained on 2950HR 
V5.4A (2 deg min-1 in air) and 2960 SDT V3.0F (10 deg min-1 in air) respectively. 
  
Materials 
Tetraethylorthosilicate (TEOS), phenylethyltrimethoxysilane (Ph-TMS) and  
n-cetyltrimethylammonium bromide (CTAB) were purchased (Aldrich) and used as received. 
Magnetite nanoparticles were prepared by co-precipitation of Fe3+ and Fe2+ ions with 
NH4OH in aqueous solution by already known synthetic procedure.23,46 
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Preparation of MMSN-r 
Magnetite nanoparticles (150.0 mg) were sonicated for 12 h in a solution of CTAB 
(1.0 g, 2.7 mmol) and NaOH (3.5 mL, 2M) in water (480.0 mL).  The suspension was then 
mechanically stirred and heated to 80 ˚C before the dropwise addition of TEOS (5.0 mL, 25.7 
mmol). After additional stirring for 2 h at 80 ˚C, the as-synthesized light-brown material was 
filtrated, washed with water and methanol and air-dried. The resulting MMSNs were isolated 
by removing the surfactant template (CTAB) via calcination at 550 ˚C for 6 h with a heating 
rate of 10 ˚C min-1.  
 
Preparation of Ph-MMSN-h and MMSN-h  
Magnetite Fe3O4 nanoparticles (300.0 mg) were sonicated for 12 h in a solution of 
CTAB (2.0 g, 5.5 mmol) and NaOH (7.0 mL, 2M) in water (480.0 mL). The suspension was 
then heated to 80 ˚C under mechanical stirring followed by rapid simultaneous injections of 
TEOS (10.0 mL, 51.4 mmol) and phenylethyltrimethoxysilane (1.1 mL, 5.7 mmol). After 
additional 2 hours of stirring, material was filtered, washed with water and methanol and air-
dried. Final Ph-MMSN-h was obtained upon removal of CTAB surfactant template by 
Soxhlet extraction with solution of HCl in methanol (0.1 M) for duration of 48 h. A portion 
of the as-synthesized Ph-MMSN-h was calcined at 550 ˚C for 6 h with a heating rate of 10 ˚C 
min-1 in order to remove phenylethyl groups and surfactant molecules, which yielded 
MMSN-h material.  
 
Drug loading and release studies  
Camptothecin (2.1 mg, 6 μmol) or 9-Aminoacridine (2.3 mg, 10 μmol) were 
dissolved in methanol (3.0 mL). MMSN material (MMSN-r, Ph-MMSN-h or MMSN-h, 100 
mg) was added and suspension was stirred for 24 h. The resulting drug-loaded MMSNs 
(9AA@MMSN-r, 9AA@Ph-MMSN-h, 9AA@MMSN-h, CPT@Ph-MMSN-h and 
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CPT@MMSN-h) were filtered and washed with plenty of MeOH.  
Camptothecin loaded MMSNs were additionally washed by stirring in PBS buffer (pH=7.4, 5 
ml) for 18 hours in order to hydrolyze and remove a part of the loaded drug and thus generate 
a material which could be easily dispersed in water. Before washing with PBS, CPT@Ph-
MMSN-h was extremely hydrophobic and stayed at the surface of PBS solution. 
The amount of loaded drugs was calculated from the difference in concentration of 
drugs in PBS solution before and after the loadings, as determined by fluorescence 
spectroscopy. Standard curves were prepared and concentration of drugs was determined 
from the emission of 9-aminoacridine at 430 nm (exc. 343 nm) and camptothecin at 445 nm 
(exc. 383 nm).  
For determination of the drug release from magnetic materials, the drug loaded 
MMSN (2 mg) was added to a glass vial and the material was fixed to the internal side wall 
of the vial with a neodymium disk magnet (DA01, K&J Magnetics, Inc, 5/8’ x 1/32’, surface 
field: 1110 G, pull force 20.47 lbs), which was taped on the external surface of the vial in a 
manner which we already reported.23 PBS buffer (pH = 7.4, 2 ml) was then added to the vials 
and the samples were kept at room temperature. Aliquots of the solution were taken over 
time and fluorescence of the released drugs was measured while drug loaded magnetic 
material remained fixed on the internal side wall of the vials at all times.  
 
Cell cultures 
Chinese hamster ovarian (CHO) cells were seeded at a density of 1 × 105 cells mL-1 in 
6 well plates and allowed to attach for 24 h in D-10 medium (3 mL) at 37 ºC and 5% CO2.  
The D-10 medium consists of Dubelcco’s Modified Eagle Medium (DMEM) plus 10% 
equine serum, L-alanyl-L-glutamine, gentamicin, and penicillin/streptomycin.  The medium 
was replaced by suspensions of MMSN materials in fresh D-10 (25 μg mL-1 or 50 μg mL-1) 
and the cells were placed back into the incubator for additional 24 h. Each treatment with 
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MMSNs or drug loaded MMSNs was done as a triplicate, and a triplicate of cells incubated 
without any material was prepared as a control.  After that time, the material-containing 
media were removed and the cells were washed with fresh medium and PBS buffer. CHO 
cells from each well were harvested by trypsinization, centrifuged, resuspended in fresh D-10 
medium (1 mL) and the number of viable cells in each sample was measured by flow 
cytometry using Guava ViaCount assay (Guava Technologies, Inc.; Hayward, CA). 
 
Influence of agitated magnetic field on release kinetic of 9AA 
In order to observe the release of 9AA under the influence of magnetic agitation of 
9AA loaded MMSNs, axially magnetized neodymium disk magnets (DA01, K&J Magnetics, 
Inc, 5/8 inch  1/32 inch, surface field: 1110 gauss) were taped on top of the horizontal 
orbital shaker, as depicted on Figure S7. Sample vials containing 2 mg of the drug loaded 
MMSNs were then fixed at 1 mm or 5 mm height directly above the magnet disks. PBS 
buffer (2.0 mL, 10 mM, pH=7.4, I=154 mmol) was then added into the sample vials and the 
orbital shaker was immediately set to agitation at 110 rpm rate. To measure the release of 
9AA, 1.5 ml of the supernatant was taken periodically; the aliquots were centrifuged at 
14000 rpm for 5 min and fluorescence emission of the solution was measured at 430 nm 
(excitation at 343 nm).  
                    
Results and Discussion 
 
Synthesis and Characterization of MMSN Materials  
By modifying our previously published procedures for the synthesis of MCM-41 type 
mesoporous silica nanoparticles,22,47 we have prepared MMSN materials with different 
porous structures by a simple direct co-condensation of Fe3O4 nanoparticles and silicate 
precursors. As shown in the scanning and transmission electron micrographs (SEM and 
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TEM, respectively) (Figure 1), MMSNs with different porous structures were successfully 
synthesized. Iron oxide-containing mesoporous silica nanoparticles with radial orientation of 
mesopores (MMSN-r) (Figure 1a-c) were prepared by dropwise addition of 
tetraethylorthosilicate (TEOS).  In contrast, upon rapid injection of TEOS and phenylethyl-
TMS, as described in the experimental section, an MCM-41 type of hexagonal channel-like 
mesoporous structure was observed in the TEM images of phenylethyl-functionalized 
magnetic MSN (Ph-MMSN-h) (Figure 1e,f).  
 
 
 
Figure 1. SEM (a,d) and TEM (b,c,e,f) images of MMSN-r (a-c) and Ph-MMSN-h (d-f). 
 
Based on SEM analysis, the average diameter of MMSN-r and Ph-MMSN-h was 
calculated to be 123 ± 46 nm and 141 ± 34 nm, respectively. The average diameter of 
magnetite nanoparticles was estimated from TEM images to be 11.9 ± 2.0 nm. CTAB 
surfactant template was removed from Ph-MMSN-h by Soxhlet extraction with HCl/MeOH 
solution, which did not hydrolyze the silica-embedded iron oxide nanoparticles.  However, 
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we observed that the usual method of surfactant extraction (stirring in a solution HCl/MeOH 
at 60 ˚C) resulted in the undesired hydrolysis of iron oxide and consequently led to formation 
of a non-magnetic material after 3 h of reaction. Evidently Soxhlet extraction method 
afforded milder conditions for CTAB removal due to slow evaporation of HCl and 
continuous extraction by methanol. The presence of phenylethyl groups in the material after 
CTAB-removal was confirmed by FT-IR spectroscopy (Figure S2, Table S1) and TGA 
analysis (Figure S3). Non-functionalized MMSN-h material was obtained by removing the 
phenylethyl moieties and CTAB molecules by calcination at 550 ˚C for 6 h.  
The N2 sorption analyses of the materials (Figure S4, Table 1) reported a type-IV 
BET isotherm characteristic of MCM-41 structure with high surface area for all 
nanomaterials. The BJH pore size distribution revealed the mesoporous character of the 
materials with narrow pore size distribution. After calcination of Ph-MMSN-h the XRD 
reflections (Figure 2) of MMSN-h were shifted to a higher Bragg angle implying a 
contraction of the mesoporous silica. Since the distance between the [100] planes can be 
calculated from the Bragg’s equation to be 3.62 nm for Ph-MMSN-h and 3.32 nm for 
MMSN-h, which is a 9% decrease, the average pore diameter in Ph-MMSN-h, as formed by 
the SiO2 framework, is expected to be around 2.8 nm, obtained after the 9% correction. 
However, the BJH analysis of Ph-MMSN-h gave the result of lower then 2 nm for the 
average pore diameter, due to the presence of phenylethyl moieties. 
 
Table 1. BET and BJH data for MMSN-r, Ph-MMSN-h and MMSN-h materials 
 BET surface area [m2 g-1] 
BJH pore 
Diameter [nm] 
Drug loading 
(9AA or CPT) 
[μmol g-1 MMSN] 
MMSN-r 965 2.8 N.A. 
Ph-MMSN-h 1089 ≤2 N.A. 
MMSN-h 1196 2.6 N.A. 
9AA@MMSN-r 888 2.8 19.9 
9AA@Ph-MMSN-h 972 ≤2 25.0 
9AA@MMSN-h 1128 2.3 26.7 
CPT@Ph-MMSN-h 470 ≤2 46.1 
CPT@MMSN-h 1024 2.1 13.4 
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Figure 2. Powder X-ray diffraction patterns of the materials at low angle (a) inset shows the higher order 
diffraction peaks; and high angle XRD pattern (b). 
 
As depicted in Figure 2, the powder XRDs of the materials revealed that all materials 
exhibit hexagonal pore packing. In the case of Ph-MMSN-h material higher order reflections 
([110] and [200]) have diminished intensity, which is sometimes observed for materials 
synthesized by our co-condensation method.47 Mesoporous silica spheres with radial pore 
structure have been reported to exhibit the hexagonal diffraction patterns.48-50 This result was 
attributed to the hexagonal pore packing in the center of the particles. High angle XRD 
measurements of these MMSN materials showed the typical diffraction patterns of magnetite 
and maghemite nanoparticles, which are the product of magnetite oxidation upon calcination 
in air.  This is also evidenced by the small positive peak at 374 ˚C in thermogravimetric 
analysis-differential thermal analysis (TGA-DTA) for Ph-MMSN-h (Figure S3c). The color 
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change of the Ph-MMSN-h material from light brown to red upon calcination further 
supports the formation of maghemite.  
The chemical compositions of the materials were determined by the energy-dispersive 
X-ray spectrometry (EDX) and TGA. The amounts of iron were calculated to be 9.7 and 6.1 
wt% for MMSN-r and Ph-MMSN-h, respectively. The quantity of the phenylethyl groups in 
Ph-MMSN-h was calculated to be 14.8 wt%.  Field-dependent magnetization curves (Figure 
3) show that the materials are superparamagnetic, since there was no hysteresis observed at 
room temperature. At 5 K, both curves show hysteresis with remnant magnetization of 1.5 
emu g-1 and 2.8 emu g-1 and coercivity field (169 Oe and 188 Oe) for Ph-MMSN-h and 
MMSN-r, respectively. Saturation magnetizations for Ph-MMSN-h are 4.9 emu g-1 and 5.8 
emu g-1 while for MMSN-r are 8.8 emu g-1 and 10.2 emu g-1 at 300 K and 5 K, respectively. 
The values for saturation magnetization are consistent with lower weight ratio of iron-oxide 
nanoparticles in the core of Ph-MMSN-h compared to MMSN-r.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Magnetization curves for MMSN-r and Ph-MMSN-h at 300 K. Inset shows magnetization 
curves at 5 K. 
 
It is interesting to note that the formation of different mesoporous structures appear to 
be dependent on the rate of silicate condensation in the presence of well-dispersed iron oxide 
nanoparticles and CTAB micelles. In the case of MMSN-r, TEOS was added dropwise. The 
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formation of MMSN-r was first observed when approximately 40% of the TEOS was 
introduced. Given the fact that the concentration of silicate was low in comparison to iron 
oxide nanoparticles and CTAB, the condensation would likely take place around or on the 
surface of the iron oxide nanoparticles serving as nucleation seeds. Subsequent build up and 
gradual growth of mesoporous silica layers would give rise to the magnetic MSN particles 
with radial pore orientation. Similar mechanism was already suggested for mesoporous silica 
spheres with radial pores.49,50 In contrast, the synthesis of Ph-MMSN-h involved rapid and 
simultaneous injections of TEOS and Ph-TMS. The formation of Ph-MMSN-h was observed 
in less then one minute. In this case, the concentration of TEOS was high and the 
condensation between silicate precursors around CTAB micelles would be preferred over the 
interaction with Fe3O4 surface. Magnetic nanoparticles were thus incorporated into the 
typical MCM-41 type of mesoporous silica framework.  
In addition, we note that absence/presence of phenylethyl functionality was not 
crucial for yielding radial or hexagonal porous structure respectively. In the case of rapid 
injection of TEOS without addition of organosilane the porous structure of the obtained 
material was also hexagonal. However, we observed that the presence of phenylethyl moiety 
allowed the even distribution of highly dispersed magnetite nanoparticles within the silica 
framework. When phenylethyl-TMS was not injected along with TEOS, the resulting 
material was a mixture of different shapes and sizes of MMSN nanoparticles, which also 
contained large conglomerates of Fe3O4, typically seen on the edges of bigger, bean-like 
particles (Figure S5). Highly dispersed Fe3O4 nanoparticles within evenly distributed MMSN 
nanoparticles were also seen in the case of material synthesized by rapid injection of 3-
bromopropyltrimethoxysilane along with TEOS (Figure S6).   
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Drug Loading and Release Studies  
Magnetic materials were further investigated as possible carriers for drug delivery to 
cancerous cells. Camptothecin and 9-aminoacridine were chosen as loading drugs, which 
represent a hydrophobic and hydrophilic drug, respectively. Release of the drugs was 
monitored under simulation of controlling the location of the drug delivery system by an 
externally applied magnetic field. Inexpensive commercially available neodymium disc 
magnet, which was taped to the external wall of the sample vial, as described in experimental 
section, was efficient in keeping the drug delivery system fixed to the internal walls of the 
vial. We envision that the same straightforward approach may be applicable for in vivo tumor 
site targeting. Hydrophilic 9AA hydrochloride was first adsorbed on the surface of MMSN-r, 
MMSN-h and Ph-MMSN-h from a methanol solution. The amounts of loaded drugs and BET 
data for the corresponding materials are specified in Table 1. More 9AA was adsorbed on the 
MMSN-h materials probably due to the higher surface area. Release of the drug was 
monitored in PBS solution and is represented in Figure 4a. It was observed that different 
porous structure did not affect the release kinetics of the drug, as MMSN-r and MMSN-h 
exhibited similar release profiles. However, a slightly higher percentage of loaded 9AA was 
released in the case of MMSN-r probably because the radial structure has more mesopore 
entrances and hence the adsorbed molecules within them are more accessible to the 
surrounding medium. 
Interestingly, the release of 9AA from phenylethyl-functionalized MMSN-h was very 
low, even though the amount of loaded drug was comparable to the loadings on MMSN-h 
and MMSN-r. These data suggest that the hydrophobic pore interior, as formed by 
phenylethyl functionality, hinders the release of 9AA. Most of the drug molecules are 
probably attached through electrostatic interactions and hydrogen bonds between 9AA 
molecules and surface silanol groups on MMSN, with a possible contribution from π-π 
stacking between the drug and phenyl groups inside the mesopores. Hence, in order to release 
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the drug, water molecules and ions from PBS buffer need a clear access to the site of 9AA 
adsorption, where the hydrogen bond exchange and ion metathesis would take place. 
However, this process seems to be hindered in the case of 9AA@Ph-MMSN-h due to 
hydrophobic environment around adsorbed 9AA molecules. Since the amount of 
hydrophobic phenylethyl moieties inside the mesopores is very high (14.8 wt%) and the 
mesopores of Ph-MMSN-h have a small diameter (≤ 2 nm), diffusion of water clusters into 
the narrow hydrophobic mesopores is probably not a favorable process. In fact, we believe 
that wetting of those mesopores happens only at the entrance level, which as a consequence 
yields in low released amount of 9AA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Released portion of the loaded drug from: (a) 9-aminoacridine and (b) camptothecin loaded 
materials. 
 
In order to further investigate the influence of phenylethyl moiety on drug release, 
hydrophobic drug camptothecin was adsorbed on Ph-MMSN-h and MMSN-h in a similar 
manner to 9AA loading and the release kinetics were measured in PBS solution (Figure 4b). 
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Interestingly, the release of the drug from Ph-MMSN-h was now much larger and there was 
almost no release from MMSN-h material. In addition, the drug loading was also much larger 
in the case of CPT@Ph-MMSN-h compared to CPT@MMSN-h and BET measurements 
(Table 1, Figure S4d) revealed that adsorption of camptothecin on Ph-MMSN-h caused a 
large decrease in surface area while there was only a minor influence on surface area upon 
adsorption on MMSN-h. These results suggest that phenylethyl moiety promotes the 
deposition of CPT probably through π-π stacking and van der Waals interactions. Phenyl 
moieties were already reported to increase the amount of loaded camptothecin in liposomal 
delivery vehicles as well as to increase stability of the self-assembled structures.51 Improved 
ability of CPT loaded Ph-MMSN-h to release the anticancer drug upon dissolution in PBS 
can be explained in terms of improved wetting of the mesopores. Even though CPT is a 
hydrophobic molecule, it is known that it undergoes hydrolysis of its lactone ring in PBS 
solution.52 It is a fast process even at pH 7.4 in PBS buffer and it produces negatively 
charged carboxylate analogue of the drug which is not biologically active. Hence, we believe 
that gradual hydrolysis of CPT within the mesopores tampers the hydrophobic environment 
inside the channels and allows better diffusion of PBS solution into the mesopores. Once the 
wetting was enabled, a large amount of the drug that was relatively weakly attached through 
π -π stacking interactions with phenyl groups in Ph-MMSN-h was able to diffuse away from 
the material. Since almost 4 times lower amount of CPT was loaded on MMSN-h and it was 
attached exclusively on the silica surface, the release kinetics of the drug on Figure 4b 
showed much lower release. Non-functionalized, non-magnetic mesoporous silica 
nanoparticles were already used to load camptothecin and also a very small release of the 
drug in PBS was observed.53  
Curiously, even though 9AA is a hydrophilic molecule, no promotion of wetting of 
the mesopores was noted in the case of 9AA@Ph-MMSN-h, as very low drug release was 
observed. We believe that this result is due to orientation of positively charged amine 
 47
moieties of 9AA molecules toward silica walls and ion coupling with surface silanols. If we 
consider that in addition to that ion pairing 9AA forms peripheral π-π stacking interaction 
with phenyl moieties inside the mesopores, the channels of 9AA@Ph-MMSN-h may have 
stayed hydrophobic even with loaded hydrophilic 9AA.  Oppositely, hydrolyzed CPT would 
tend to rotate its negative charge away from silica surface, which means straight toward 
incoming PBS solution. 
 
Viability Studies on CHO Cells  
To test the drug delivery capabilities of our materials in vitro, viability studies on 
CHO cells were done and results are represented in Figure 5. While 9AA loaded Ph-MMSN-
h was not cytotoxic at concentration of 50 μg mL-1, number of viable cells decreased to 55% 
upon treatment with the same concentration of 9AA loaded MMSN-h. Clearly, the greater 
amount of released drug in case of 9AA@MMSN-h induced the difference in viability. The 
reverse effect of organic functionalization was confirmed in the case of camptothecin loaded 
materials. If treated at the concentration of 25 μg mL-1, only CPT@Ph-MMSN-h induced 
CHO cell death and their final amount decreased to 57.5 % of the total number of cells, as 
compared to the control sample. We also observed that 9AA loaded materials had lower 
cytotoxic activity than CPT loaded MMSNs since no influence on viability was noted in the 
case of treatment with 9AA@MMSN-h at a concentration of 25 μg mL-1. This effect can be 
attributed to a higher cytotoxicity of camptothecin rather than to the difference in quantities 
of released drug as similar amounts were released from 9AA@MMSN-h and CPT@Ph-
MMSN-h after 24 h in PBS solution (2.9 μmol g-1 of CPT and 3.25 μmol g-1 of 9AA). Since 
only non-hydrolyzed camptothecin molecule is cytotoxic, the viability results indicate that 
plenty of CPT molecules were successfully released from Ph-MMSN-h and delivered to 
cancerous cells in a native, bioactive form.  
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Figure 5. Percentage of live CHO cells upon 24 h incubation with: (a) 50 μg mL-1 and (b) 25 μg mL-1 
dosage of corresponding MMSN materials normalized to the untreated cells (control). 
 
Drug release kinetics as a function of externally applied agitated magnetic field 
In order to test the capability of externally applied magnetic field to influence the 
drug delivery from MMSN based drug carriers, we set the experiment as depicted on Figure 
S7. Neodymium disk magnets were placed below the vials containing drug loaded MMSN in 
PBS solution. Position of the vials was fixed to iron stands while motion of disk magnets 
below the vials caused movement of drug loaded MMSN inside the vials. Circular motion of 
MMSN materials along the bottom of the vials was very explicit. As can be seen on figure 6, 
agitation of 9AA loaded MMSN materials, caused by externally applied magnetic field, 
clearly increased the rate of drug release. This result can be explained by faster mass transfer 
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of PBS solution into the mesopores as well as faster detachment and transfer of 9AA 
molecules to the bulk solution, under conditions of agitated versus fixed drug carries. We 
also tested if magnet induced agitation would improve wetting of 9AA@Ph-MMSN-h 
mesopores and increase the released drug amount (Figure 6b). Only slight increase in rate of 
9AA release from Ph-MMSN-h was noticed and no improvement of release capacity was 
noted for applied conditions. Finally, we monitored the influence of different strength of 
magnetic field on the rate of drug release (Figure 6c). If the distance between disk magnets 
and sample vials was increased by a factor of 5, slower agitation rate of MMSN materials 
was clearly evident, which resulted in lower rate of 9AA release.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Release curves for: (a) 9AA@MMSN-r and 9AA@MMSN-h and (b) 9AA@Ph-MMSN-h with 
and without presence of magnetic field agitated at 110 rpm rate. (c) Influence of different magnetic pull 
on release of 9AA; Comparison of the release under 110 rpm agitation with the sample closely above the 
magnet (h=1 mm) and the release when sample was at the 5 mm height above the magnet. Release data 
for all results are normalized to the total released drug amount, which was set to 100 %. 
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Conclusions 
 
A series of core-shell, iron-oxide nanoparticle embedded superparamagnetic 
mesoporous silica nanoparticle materials with radial and hexagonal porous structures were 
successfully prepared via a facile condensation method. We have demonstrated that the 
loading and release of anticancer drugs, 9-aminoacridine and camptothecin, were influenced 
by the presence of phenylethyl moiety inside the mesopores of MMSN materials. Release of 
hydrophilic 9-aminoacridine is hindered and the release of hydrophobic camptothecin was 
promoted by the organic functionalization. The cell viability assay supported the release 
kinetic results. Camptothecin loaded phenylethyl functionalized material was cytotoxic while 
CPT loaded non-functionalized material did not affect the viability of CHO cells at  
25 μg ml-1 concentration. In case of 9AA loaded materials, feeding the cells with 
9AA@MMSN-h at 50 μg ml-1 concentration induced a decrease in number of viable cells 
while addition of 9AA@Ph-MMSN-h did not influence the cell viability. Finally, we 
demonstrated the ability of externally applied agitated magnetic field to control the rate of 
drug release from magnetic drug delivery carriers.  
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Appendix A 
 
 
 
 
 
 
 
 
 
 
          (a) (b) 
 
 
 
 
 
 
 
 
(c) (d)      
 
Figure S1. Additional TEM images of MMSN-r (a, b) and Ph-MMSN-h (c, d).  
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Appendix B 
 
 
Figure S2. Infrared spectrum of Ph-MMSN-h. 
 
 
Table S1. Assignment of the bands from IR spectrum of Ph-MMSN-h 
 
Wavenumber (cm-1) 3077 3058 2953 2927 2853 1596 1462 1432 
Assignment Phenyl C-H st 
Phenyl 
C-H st 
Ethyl 
C-H st 
Ethyl 
C-H st 
 
Ethyl 
CH st 
 
Phenyl 
C-C 
Ethyl 
C-C δ 
Phenyl 
C-C  
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Appendix C 
 
 
 
a) 
 
 
 
 
 
 
b) 
 
 
  
 
 
 
c) 
 
 
 
 
Figure S3. TGA data for (a) MMSN-r-as synthesized, (b) Ph-MMSN-h and (C) DTA-TGA for  
Ph-MMSN-h. 
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Appendix D 
 
 
 
 
 
 
 
 
                           (a)                                                                  (b) 
 
  
 
 
 
 
 
 
                          (c)                                                                  (d) 
                                  
Figure S4. BET nitrogen adsorption/desorption isotherms for: (a) MMSN-r and  9AA@MMSN-r, (b) 
MMSN-h and Ph-MMSN-h, (c) 9AA@MMSN-h and 9AA@Ph-MMSN-h and (d) CPT@MMSN-h and 
CPT@Ph-MMSN-h. Insets show BJH average pore diameter distribution.  
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Appendix E 
 
 
 
 
 
 
 
 
 
                                                                a) 
                             
                                    
 
 
       
 
   
                   
                                                                                                                               
                           b)                                                     c) 
Figure S5. SEM (a) and TEM images (b, c) of MMSN material synthesized without addition of Ph-TMS 
with TEOS.  
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Appendix F 
 
 
 
 
 
 
 
 
 
    
                                                     a)                                                                                 
                       b)                                                                    c) 
Figure S6. SEM (a) and TEM images (b, c) of MMSN material synthesized by addition of 3-
bromopropyltrimethoxysilane along with TEOS. 
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CHAPTER 4. MAGNETIC DRUG DELIVERY SYSTEM FOR 
PHOTOSENSITIVE TRIGGERING OF CAMPTOTHECIN  
RELEASE TO CANCER CELLS 
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Abstract 
 
Magnetic mesoporous silica nanoparticles were loaded with the anticancer drug 
camptothecin and mesopore entrances were blocked with 2-nitro-5-mercaptobenzyl alcohol 
functionalized CdS nanoparticles through a photocleavable carbamate linkage. Camptothecin 
release from this magnetic drug delivery system was successfully triggered upon irradiation 
with UV light. Photosensitive delivery of the anticancer drug was monitored by viability 
study on Chinese hamster ovarian cells. A cooperative anticancer effect of the capping CdS 
nanoparticles and loaded camptothecin was observed upon exposure of the cell cultures 
treated with drug loaded material to low power UV light (365 nm). 
 
Introduction 
 
The development of drug delivery systems (DDS) for cancer therapy has received 
much attention during the recent years. Due to severe toxic effects that anticancer drugs 
inflict on healthy tissues, one of the goals for research on DDS has been to devise a system 
with the ability to target the delivery of drugs to specific regions of the body, i.e. cancerous 
tissue.[1-4] There are several characteristics of tumor tissues that are currently exploited for 
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targeted drug delivery. The enhanced permeability and retention (EPR) effect is the first of 
these properties, which facilitates the spontaneous accumulation of macromolecules in the 
extracellular medium of tumor tissue.[5] Hence, the primary targeting design is the 
construction of DDS as nanometric macromolecular assemblies. Additional cancer targeting 
can be achieved by modification of a surface of DDS with ligands which have a specific 
interaction with overexpressed receptors on the luminal side of tumor clusters. Folic acid and 
the Arg-Gly-Asp (RGD) tripeptide were shown as efficient ligands for this purpose.[6] 
Alternatively (or in addition to other forms of targeting), the site of drug delivery can be 
actively targeted by an external stimulus. For example, the drug carriers can be magnetically 
active which would open the possibility to control the location of a DDS by an externally 
applied magnetic force.[7] Additionally, release of the drug from a DDS can be actively 
controlled by an external stimulus. That is, the drug carrier would not release its cargo unless 
triggered by a controlled external incentive, for instance by light irradiation.[8, 9] 
We have previously demonstrated the utilization of macromolecules and quantum 
dots as “caps” for entrapment of various molecules in the pores of mesoporous silica 
nanoparticles (MSN).[10-12] The molecules are not released from the mesopores unless 
triggered by chemical reagents. MSN is suitable material for the construction of drug carriers 
due to its high surface area (> 700 m2/g), tunable pore diameter (2-30 nm), narrow pore size 
distribution and particle diameter (typically 100 - 200 nm) which is in range to benefit from 
EPR effect of tumor tissue. In addition we have shown that these nanospheres can effectively 
penetrate the cell membrane, usually through clathrin mediated endocytosis.[13] Besides of its 
applications in drug delivery, MSN has been proven applicable for selective catalysis, 
sensing and separation techniques.[14-16] 
We have also previously reported on magnetic mesoporous silica nanoparticles 
(MMSN).[17] This is a core-shell type of material with magnetic iron oxide nanoparticles as 
the core and mesoporous silica framework as the shell of nanospheres. The material still has 
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all of the drug carrier-beneficial properties of MSN with an added benefit of magnetic 
activity. We also showed that MMSN is responsive to the action of externally applied 
magnetic field, exerted by magnetic force of an inexpensive neodymium magnet (1110 G). 
These results facilitate the devising of a DDS which would contain the possibility of applying 
an external nondestructive force, such as a magnetic field, to control the location of the drug 
carriers both in vitro and in vivo. This method has been shown to yield a significant 
improvement in the efficiency and selectivity of the drug release.[7] 
Hence, in a continuing effort to devise an ultimate targeting DDS, which we imagine 
would be capable of delivering an exact amount of drug to a precise location; we developed 
magnetically active DDS with an ability to release anticancer drugs upon UV light 
irradiation. We report on a CdS nanoparticle-capped magnetic mesoporous silica based DDS 
for a UV radiation triggered release of anticancer drug camptothecin (CPT). This drug and its 
derivatives are known to inhibit DNA enzyme topoisomerase I and have been used in 
chemotherapy for a variety of cancer types.[18, 19] Viability studies  confirmed the capability 
of the DDS to deliver camptothecin to Chinese hamster ovarian (CHO) cells and induce cell 
death upon irradiation with low power UV lamp.   
 
Experimental Section 
 
Instrumental Methods  
Powder XRD diffraction data were collected on a Scintag XRD 2000 X-ray 
diffractometer using Cu Kα radiation. Nitrogen adsorption and desorption isotherms, surface 
area and average pore diameter were measured using a Micromeritics ASAP2000 
sorptometer. Sample preparation included degassing at 100 °C for 6 h. Specific surface areas 
and pore size distributions were calculated using the Brunauer-Emmett-Teller (BET) and 
Barrett-Joyner-Halenda (BJH) methods, respectively. Particle morphology of the materials 
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was determined by scanning electron microscopy (SEM) using a JEOL 840A scanning 
electron microscope. Transmission electron microcopy (TEM) examination with energy 
dispersive X-ray analysis (EDX) was completed on a Tecnai G2 F20 electron microscope 
operated at 200 kV. 
 
Materials 
Tetraethylorthosilicate (TEOS), n-cetyltrimethylammonium bromide (CTAB),  
3-isocyanatopropyltriethoxysilane (Gelest), 5,5'-dithiobis(2-nitrobenzoic acid) and 
camptothecin (CPT) were purchased from Aldrich and used as received. Magnetite 
nanoparticles were prepared by co-precipitation of Fe3+ and Fe2+ ions with NH4OH in 
aqueous solution by a previously reported synthetic procedure.[11, 20] 2-Nitro-5-
mercaptobenzyl alcohol (NMBAl) was synthesized by reduction of 5,5'-dithiobis(2-
nitrobenzoic acid) (Ellman’s reagent) following the reported procedure.[21] 
 
Preparation of magnetic mesoporous silica nanoparticles (MMSN): 
Procedure for the preparation of MMSN used in this study was already reported 
recently.[17] Namely, magnetite Fe3O4 nanoparticles (300.0 mg) were sonicated for 12 h in a 
solution of CTAB (2.0 g, 5.5 mmol) and NaOH (7.0 mL, 2M) in nanopure water (480.0 mL). 
The suspension was then heated to 80 ˚C under mechanical stirring followed by rapid 
injection of TEOS (10.0 mL, 51.4 mmol). After additional 2 hours of stirring, the material 
was filtered, washed with water and methanol and air-dried. Final MMSN was obtained upon 
removal of surfactant molecules by calcination at 550 ˚C for 6 h with a heating rate of 10 ˚C 
min-1. 
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Synthesis of cadmium-sulfide nanoparticles capped with 2-Nitro-5-mercaptobenzyl 
alcohol (CdS-NMBAl): 
CdS nanoparticles were prepared by modification of a published procedure for 
synthesis of thioglycerol capped CdS nanoparticles.[22] Ethanol solutions (50 ml,  
5 mM) of cadmium acetate, sodium sulfide and NMBAl were separately prepared and pH of 
all three solutions was fixed to 6 by addition of concentrated acetic acid and ethanol solution 
of sodium acetate. Solutions were degassed by flushing with Ar and were kept under Ar 
throughout the synthesis. Cadmium acetate and NMBAl were then mixed under vigorous 
stirring and the solution of Na2S was added dropwise into the mixture while the whole 
solution was stirred and protected from light. Addition of sodium sulfide was the dark. 
Solvent was then evaporated and acetone was added to the oily residue until CdS-NMBAl 
precipitated. The product was centrifuged, washed with acetone and dried in liophylizer. 
Yield: 0.1 g. Elemental analysis: found C: 23.085 %, H: 3.0725 %,  
N: 0.0525 %, S: 1.425 %. Theoretical for: (CdS)13.65(C7H6O3NS)(CH3COO)321.4. 
 
Loading of camptothecin into the mesopores of MMSN and capping with CdS-NMBAl: 
The solutions in this procedure were kept constantly under Ar. CdS-NMBAl  
(120 mg) was dissolved in 4ml of dry DMF after which 3-isocyanatopropyltriethoxysilane  
(0.1 mmol, 26 μl) was added and the solution was stirred in dark for 24 h. During the same 
time MMSN (100 mg) and camptothecin (4 mg) were stirred in 2ml of water-free DMF. 
Then camptothecin (8 mg) was added to the solution containing pre-reacted CdS-NMBAl 
and 3-isocyanatopropyltriethoxysilane, the solution was stirred for additional 15 minutes and 
then added to the suspension containing MMSN and CPT. New suspension was then stirred 
for 20 h under heating at 125 ºC in order to graft CdS-NMBAl on the surface of MMSN and 
entrap CPT in the process. The new material CdS-NMBAl-CPT@MMSN (CCM) was 
filtered, washed with DMF, water and methanol and dried in lyophilizer.  
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Loading of the drug was determined by the absorption of residual CPT from the 
filtrate solution after evaporation of solvents and redissolving in DMF. Final loaded amount 
was determined to be 50mg of CPT/g of MMSN, by comparison of the absorption at 364 nm 
with previously prepared standard curve. 
For determination of the drug release from CCM, the drug loaded magnetic material  
(2 mg) was added to glass vials and the material was fixed to the internal side wall of the vial 
by the influence of magnetic field of a neodymium disk magnet (DA01, K&J Magnetics, Inc, 
5/8’ x 1/32’, surface field: 1110 G, pull force 20.47 lbs), which was taped on the external 
surface of the vial in a manner which we already reported.[11] PBS buffer (pH = 7.4, 2 ml) 
was then added to the vials and samples were kept in dark, at room temperature. Aliquots of 
the solution were taken over time and the fluorescence of the released drug was measured at 
445 nm (exc. 383 nm). After establishing a steady release for the material in dark, one of the 
samples was subjected to UV irradiation for 30 minutes with a Rayonet RPR-100 
photoreactor equipped with 16 RPR-3500 lamps. The lamps have an emission maximum at 
350 nm and measured light intensity was 5.5 mW/cm2 at the center of the photoreactor. Light 
intensity of the irradiation source was measured with Spectroline DSE-2000HA/L 
Radiometer/Photometer. After irradiation, the sample was again kept in dark and flurescence 
measurements continued. 
 
Cell cultures 
All experiments were done in triplicate for each of the following designations: CTRL-
control cells without any added material; CCM-the cells treated with CPT loaded material. 
i.e. CdS-NMBAl-CPT@MMSN; CM-the cells treated with empty shell, i.e. CdS-NMBAl-
MMSN. All of the samples were also either kept in dark (DARK) at all times or were kept in 
dark except when subjected to irradiation (IRR) for 30 minutes, as described below. Control 
samples, i.e. samples without added material were treated in the same manner as the samples 
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with added materials, during all steps of the experiment. Chinese hamster ovarian (CHO) 
cells were seeded at a density of 1 × 105 cells mL-1 in 6 well plates and allowed to attach for 
24 h in D-10 medium (3 mL) at 37 ºC and 5% CO2. The D-10 medium consists of Dubelcco’s 
Modified Eagle Medium (DMEM) plus 10% equine serum, L-alanyl-L-glutamine, 
gentamicin, and penicillin/streptomycin. The medium was then replaced by suspensions of 
prepared materials at specific concentrations (0 μg/mL for CTRL, 10 μg/mL and 25 μg/mL 
for CCM and 25 μg/mL for CM) in a fresh medium without added serum. Serum was not 
used in this case in order to increase endocytosis efficiency of the materials. The cells were 
then protected from light and placed back into the incubator for additional 5 h. After that 
time the suspensions/solutions were removed, the cells were washed with PBS buffer and 
fresh aliquots of D-10 medium without materials were added. This procedure was done in 
order to ensure that only endocytosed material, which cannot be washed out, is responsible 
for any effect on cell viability. The samples designated as IRR were then immediately 
subjected to UV irradiation for 30 minutes. That is, 6 well culture plates were placed below 
Spectroline UV lamp model ENF-240C (115 V, 60 Hz, 0.2 A, measured light intensity = 1.0 
mW/cm2).  At the same time DARK samples were kept in the dark, outside of the incubator. 
After the 30 minutes, all cells were protected again from light and placed back in the 
incubator for additional 20 h. CHO cells from each well were then harvested by 
trypsinization, centrifuged, resuspended in fresh D-10 medium (1 mL) and the number of 
viable cells in each sample was measured by flow cytometry using Guava ViaCount assay 
(Guava Technologies, Inc.; Hayward, CA). 
 
 
 
 
 66
Results and discussion 
 
The synthesis and full characterization of magnetic mesoporous silica nanoparticles 
were previously reported.[17] We devised a facile synthetic method for preparing core-shell 
MMSN by co-condensation of magnetite nanoparticles with silicate precursors in basic 
solution, in the presence of cetytrimethylammonium bromide as a structure templating agent. 
The new magnetic analogues of MSN contained Fe3O4 nanoparticles in the core and a 
mesoporous silica framework as the shell of MMSN. When we applied fast addition of silane 
precursors into the reaction mixture containing surfactant template and well dispersed 
magnetite nanoparticles in basic conditions, we obtained MMSN with hexagonal pore 
packing, analogous to our typical MSN material. Final magnetic material was obtained after 
removal of surfactant by calcination in air, which also oxidized magnetite nanoparticles to 
maghemite nanoparticles in the core of MMSN. This material was further used for loading 
anticancer drug camptothecin into the mesopores and capping with 2-Nitro-5-
mercaptobenzyl alcohol functionalized cadmium-sulfide nanoparticles (CdS-NMBAl). 
Ortho-nitrobenzyl moiety is known for several decades as effective photoresponsive 
protection group.[23] Preparation steps for the final drug loaded MMSN is depicted in Scheme 
1. CdS nanoparticles were synthesized by modification of published procedure for synthesis 
of thioglycerol functionalized CdS nanoparticles.[22] Synthesis was conducted by reacting 
cadmium-acetate and 2-nitro-5-mercaptobenzyl alcohol in ethanol solution, buffered with 
sodium-acetate/acetic acid to pH 6.   
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Scheme 1. Preparation of 2-nitro-5-mercaptobenzyl alcohol (NMBAl) functionalized cadmium-sulfide 
nanoparticles (CdS-NMBAl) and their application for capping the mesopores of MMSN and entrapment 
of camptothecin. ICP-TES = 3-isocyanatopropyl-triethoxysilane. 
 
Ethanol was evaporated after the reaction and CdS-NMBAl was precipitated by 
addition of acetone. IR spectrum of CdS-NMBAl is dominated by the presence of acetate 
ions which precipitated with CdS-NMBAl nanoparticles. Strong carboxylate stretch 
vibrations are evident at 1575 cm-1 and 1417 cm-1 and characteristic δ(COO-) at 671 cm-1 
(Figure 1). However, in the spectrum of CdS-NMBAl we still noticed the presence of 
symmetric stretch of NO2 group and a doublet arising from benzyl alcohol moiety (Table 1). 
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b) 
 
 
 
 
 
Figure 1. IR spectra of a) NMB-alcohol and b) CdS-NMBAl 
 
Table 1. IR spectra band assignment for NMB-alcohol and CdS-NMBAl 
 
CdS-NMBAl displayed typical UV-VIS absorbance and fluorescence characteristics 
of CdS quantum dots (Figure 2). UV-VIS  absorbance of CdS-NMBAl in DMF revealed 
presence of absorption band of CdS nanoparticles with maximum of the band centered at 360 
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nm and band edge (λe ) at 440 nm. Diameter of CdS nanoparticles was calculated to be 3.27 
nm which was obtained from band edge value based on Henglein’s empirical curve:[24] 
2R(CdS) =0.1/(0.1338-0.0002345λe) nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. a) UV-VIS and b) fluorescence (exc. 350 nm) spectra of CdS-NMBAl 
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Loading of the drug and capping of mesopores was done in dry DMF. Camptothecin 
was first stirred in a suspension of MMSN for 24 h in order to allow for diffusion of the drug 
into the mesopores. CdS-TNBAl was separately coupled with isocyanatopropyl-TMS to form 
carbamate linkage and then mixed with CPT before mixing the two solutions and grafting 
CdS caps on drug filled MMSN. TEM images of the final drug filled material (CPT@CdS-
NMBAl-MMSN) are shown on Figure 3. 
 
 
 
 
 
 
 
 
 
 
                         (a)                                                             (b) 
Figure 3. Transmission electron images (TEM) of CPT@CdS-NMBAl-MMSN; (a) MMSN nanoparticles 
engulfed by CdS quantum dots and (b)  the image showing iron-oxide nanoparticles inside the 
mesoporous matrix and CdS nanoparticles on the pore entrances. 
 
Figure 3a shows MMSN material engulfed in CdS-NMBAl matrix. It seems that 
during the capping procedure, which was done at high temperature, in situ prepared 
triethoxysilane functionalized CdS nanoparticles condensed with each other to a certain 
degree and formed the matrix, in addition to grafting the matrix on MMSN surface. Figure 3b 
shows a region with smaller amount of CdS caps clearly showing the presence of maghemite 
nanoparticles inside MMSN, and CdS nanoparticles capping the mesoporous channels. 
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Nitrogen adsorption/desorption isotherms (Figure 4) revealed that after capping, BET 
isotherm changed from type IV to type II. Type IV surface is characteristic for mesoporous 
while type II for microporous materials. BJH analysis confirms these results as the average 
pore diameter decreases after capping from 2.6 nm to a value below 2 nm, which indicates 
partial blocking of the mesopores. BET surface area for the material before capping was 859 
m2/g, which changed to 749 m2/g for CPT@CdS-NMBAl-MMSN, and 688 m2/g for CdS-
NMBAl-MMSN. These values reveal that the encapsulation of the drug in the mesopores was 
not very efficient. Even though CdS caps clearly influenced the values for BJH average pore 
diameter, there was still plenty of available room for nitrogen molecules to enter the 
mesopores and adsorb on available surface area, during the BET analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. BET nitrogen adsorption/desorption isotherms for MMSN,  
CPT@CdS-NMBAl-MMSN and CdS-NMBAl-MMSN. Inset shows BJH pore size distributions. 
 
 Release of camptothecin was measured in PBS buffer. Since the DDS had magnetic 
properties we were able to monitor the release of the drug while DDS was fixed to the 
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internal side wall by the force of external magnetic field. This procedure was used as a 
simulation of targeting the treatment area by the application of an external magnetic field. 
We compared the drug release from the DDS that was kept continuously in the dark with the 
one that was subjected to irradiation for 30 minutes (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Release of camptothecin from CPT@CdS-NMBAl-MMSN while protected from light at all 
times (empty squares) and while protected from light at all times except for 30 min period under 
irradiation with UV light (350 nm) starting with the point marked by arrow (black diamonds).  
 
As evidenced by the drug release kinetics, CPT release was successfully triggered by 
UV light irradiation. Almost no release of the drug was noticed if DDS was constantly kept 
in dark. However, upon 30 minutes of UV irradiation, the drug concentration in solution 
increased, as evidenced by the increase in drug fluorescence.  This increase in fluorescence 
was clearly not due to increased concentration of CdS-NMBAl upon irradiation, because the 
system that did not contain loaded CPT (CdS-NMBAl-MMSN) did not show this increase in 
fluorescence after irradiation. 
In order to test the applicability of our DDS for drug delivery to cancer cells, we 
monitored viability of Chinese hamster ovarian (CHO) cells in the presence of  CPT@CdS-
NMBAl-MMSN (CCM) and CdS-NMBAl-MMSN (CM) material without (Dark) and with 
0 5 10 15 20 25 30
Time (h)
Fl
uo
re
sc
en
ce
 (a
.u
.)
Irradiated
Control
 73
60
80
100
120
Dark-ctrl Irr-ctrl Dark-CCM Irr-CCM
Vi
ab
le
 c
el
ls
 (%
)
exposure (Irr) to low power UV lamp. The viability of treated cells was then compared to 
non-treated, control cells (Ctrl). As depicted on Figure 6, there is no influence on cell 
viability if CHO cells were treated with CPT loaded material, if the culture was kept in dark 
(Dark-CCM). However, upon exposure to 30 minutes of UV light irradiation number of 
viable cells in sample Irr-CCM decreased to 84 % of the number of viable cells counted in 
the culture treated with the same material, but that was kept in dark (Dark-CCM).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Number of viable CHO cells upon treatment with 10 μg/ml of CCM, while keeping the cell 
cultures constantly in dark (Dark-CCM); and upon exposure to 30 min irradiation with a low power UV 
lamp and consequently keeping the culture in dark (Irr-CCM). Viability values are compared to non-
treated cells (ctrl) under the same conditions. 
 
Student T test was done by comparison of Dark-CCM and Irr-CCM series and the 
two-tailed P value equals 0.0370 which means that this difference is considered to be 
statistically significant by conventional criteria. Even though the error bars for Dark-ctrl and 
Irr-CCM overlap for this experiment, if the treatment concentration was increased to 25 
μg/ml, clear distinction between the two samples could be established (Figure 7).  
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Figure 7. Number of viable CHO cells upon treatment with 25 μg/ml of CCM. Experiment conditions and 
Figure legend is the same as for Figure 6.  
 
However, under these conditions sample Dark-CCM also showed the influence on 
CHO cell viability. This decrease in cell viability upon treatment with CPT@CdS-NMBAl-
MMSN while keeping the cell cultures in dark can be explained by the well known 
cytotoxicity of CdS nanoparticles. Still, exposure to UV irradiation of CCM sample (Irr-
CCM) clearly led to increase in toxicity. In this case, the cell cultures had 41 % less viable 
cells then the viable cells found in the sample Dark-CCM. This value is more then double 
lower then 84 %, which was determined in the treatment with 10 μg/ml of CCM, which 
agrees well with more then doubling the concentration of the DDS (from 10 to 25 μg/ml), 
which led to more then doubling released drug concentration.  
In order to prove that it is not only CdS nanoparticles that are responsible for killing 
the cells before and after irradiation, we tested the citotoxicity of the magnetic material with 
attached CdS caps but without loaded material (CdS-NMBAl-MMSN = CM), under the same 
experimental conditions (Figure 8). As can be seen, there is no increase in toxicity of CdS 
nanoparticles upon exposure of CdS-NMBAl-MMSN to UV light (Irr-CM). In addition, from 
the same figure we can conclude that CdS nanoparticles are indeed responsible for the low 
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viability measured in sample Dark-CCM and not conceivable leaking of the anticancer drug 
from the DDS in the applied conditions, because the same viability values were found in the 
sample Dark-CM. 
 
 
   
 
 
 
 
 
Figure 8. Comparison of cytotoxicity of treatments with 25 μg/ml of CPT loaded, CdS-NMBAl capped 
MMSN (CCM) and empty CdS-NMBAl capped MMSN (CM) when subjected to 30 minutes of UV 
irradiation (IRR) or kept in dark (DARK). Viability values are normalized to Dark-ctrl sample. 
 
The two-tailed P value for Irr-CCM and Irr-CM samples equals 0.0202, which means 
that this difference in viability is considered to be statistically significant by conventional 
criteria. Hence, the mesopore-loaded drug and CdS nanocaps are exhibiting cooperative 
anticancer effect for this DDS on CHO cells. We believe that this strategy can be used to 
improve the antitumor efficacy of cytotoxic drugs because: a) DDS is magnetic which allows 
targeting of the cancer tissue with externally applied magnetic field and b) capping moieties 
can act in cooperation with loaded drugs to improve the toxic potency of DDS. Since the 
drug delivery system is magnetic, we believe that it may be possible to target the cancer 
tissue in vivo rapidly enough so that CdS nanocaps are not inducing much damage to healthy 
tissue in dark. Light induced drug delivery would then further increase the selectivity of a 
treatment. Finally, magnetic analogues of mesoporous silica nanoparticles were shown 
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already as good contrast agents, which may open the possibilities for in situ monitoring of 
anticancer treatment.  
 
Conclusions 
 
We prepared magnetically active drug delivery system which is capable of delivering 
its cytotoxic cargo upon triggering the drug release with UV light. Magnetite nanoparticles-
incorporated mesoporous silica nanoparticles were loaded with anticancer drug camptothecin 
and mesopore entrances were capped with CdS quantum dots through photocleavable o-
nitrobenzyl based carbamate linkage. Camptothecin release was successfully triggered with 
UV light irradiation while location of drug delivery system was controlled with externally 
applied magnetic field. Cooperative anticancer effect of capping CdS nanoparticles and 
loaded camptothecin was observed upon treatment of Chinese hamster ovarian cells in vitro 
with CPT@CdS-TNBAl-MMSN at 25 μg/ml concentration. 
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Abstract 
 
We devised a functional supramolecular assembly with multiple-stimuli responsive 
drug release capability. The dye sulforhodamine 101 was used as a model drug and it was 
entrapped inside the mesopores of mercaptopropyl-functionalized mesoporous silica 
nanoparticles (MP-MSN) by the MSN-propylmercapto-coordinated Ru(bpy)2(PPh)3-moiety 
(bpy = 2,2’-bipyridine, PPh3 = triphenylphosphine). Upon irradiation with visible light the 
Ru-S coordination bond is cleaved which induces release of the mesopore-loaded dye 
molecules. The release of the cargo molecules was also responsive to addition of biologically 
relevant ligands, nitrogen-monoxide, histidine and imidazole. Release of both the capping 
moiety and entrapped dye was monitored in PBS solution with UV-VIS and fluorescence 
spectroscopy.  
 
Introduction 
 
Stimuli responsive drug delivery systems (DDSs) are gaining interest of the research 
community in recent years.1-3 The main goal for the research field is to safely deliver drugs to 
specific treatment area.4-6 This goal is established in order to overcome problems with 
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adverse effects of cytotoxic drugs. Typically, these DDSs are nanoscopic macromolecular 
assemblies of drugs and DDS structure-forming molecules. Mesoporous silica nanoparticles 
(MSN) in particular are attractive scaffolds for construction of such nanodevices for drug 
delivery.7-9 Drugs can be effectively loaded inside the mesoporous framework and entrapped 
by the addition of various mesopore capping agents. Cargo molecules are then released only 
upon exposure to stimuli which are able to remove capping moieties. A variety of reports on 
this topic can be found in the literature. Studies from our research group have demonstrated 
effective application of CdS,10 Fe3O4,11 and gold nanoparticles,12 as well as PAMAM 
dendrimers and insulin as capping moieties.13,14 Other authors reported the use of rotaxanes 
and other organic molecules and macromolecules for this purpose.15,16 Triggering of the drug 
release was achieved by addition of various redox agents, enzymes, anions, by UV light 
irradiation, change in temperature or pH value.  
Ideally, a functional stimulus responsive DDS would have no pre-stimulus toxicity. 
This would require application of nontoxic DDS framework as well as zero drug release 
before the triggering event. Additionally, it would be highly beneficial if DDS is responsive 
to externally applied stimulus, which could effectively target the treatment area. We reported 
previously application of UV light irradiation as an external stimulus for triggering drug 
release from MSN carrier.12 However, triggering the release with visible light would be more 
desirable because irradiation with UV light can lead to photodamage of the tissue and 
moreover, light scattering decreases with increasing irradiation wavelength.17 Thus, visible 
light would penetrate further into the tissue and would be more applicable for in vivo 
triggering of drug release.   
Recent report has shown that γ-aminobutyric acid (GABA) can be effectively 
released from a coordination compound [Ru(bpy)2(PPh3)(GABA)]Cl by visible light induced 
cleavage of Ru-GABA coordination bond.18 Herein, we report on an application of similar 
principle to deliver cargo molecules from a mesoporous silica nanoparticle-based assembly 
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upon irradiation with visible light. Sulforhodamine 101 (Sr101) molecules were loaded inside 
the mesopores of mercaptopropyl-functionalized mesoporous silica nanoparticles (MP-
MSN). The dye molecules were then entrapped inside the mesoporous space by addition of 
[Ru(bpy)2(PPh3)Cl]Cl which forms coordination bonds with mercaptopropyl moieties from 
the silica surface and prevents the cargo molecules to diffuse out into the bulk solution 
(Scheme 1). Upon irradiation with visible light the release of both the capping moieties and 
cargo Sr101 was detected by UV-VIS and fluorescence spectroscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Mesopore-encapsulation of sulforhodamine 101 by [Ru(bpy)2(PPh3)-moieties S-coordinated to 
mercaptopropyl-functionalized MSN 
  
We also monitored response of the DDS to the presence of nitrogen-monoxide, 
histidine and imidazole. These physiological species are known for their strong metal 
coordination capability, which can be utilized for substitution of Ru-coordinated  
MP-MSN and thus for the release of the loaded dye and the as synthesized 
[Ru(bpy)2(PPh3)L]2+ ions (L = incoming ligand).  
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Experimental procedure 
 
Reagents and solvents were commercially available and were used as received. 
[Ru(bpy)2(PPh3)Cl]Cl was synthesized according to the literature.18 
 
Instrumental Methods, Conditions and Parameters for Structural Characterization 
Powder XRD diffraction data were collected on a Scintag XRD 2000 X-ray 
diffractometer using Cu (Kα) radiation. Nitrogen adsorption and desorption isotherms, 
surface areas, and median pore diameters were measured using a Micromeritics Tristar 3000 
surface area and porosity analyzer. Sample preparation included degassing at 100 °C for 5 h. 
Specific surface areas and pore size distributions were calculated using the Brunauer-
Emmett-Teller (BET) and Barrett-Joyner-Halenda (BJH) method, respectively. Particle 
morphology of the material was determined by scanning electron microscopy (SEM) using a 
JEOL 840A scanning electron microscope. Fluorescence measurements were performed on 
Horiba group Fluoromax-2 fluorometer. 
 
Synthesis of mercaptopropyl-functionalized MSN material (MP-MSN)  
n-Cetyltrimethylammoniumbromide (CTAB, 1.00 g, 2.74 x 10-3 mol) was first 
dissolved in 480 mL of Nanopure water. NaOH(aq) (2.00 M, 3.50 mL) was added to CTAB 
solution, followed by adjusting the solution temperature to 353 K. TEOS (5.00 mL, 2.57 x 
10-2 mol) was first introduced dropwise to the surfactant solution, followed by dropwise 
addition of 3-mercaptopropyltrimethoxysilane (MP-TMS) (0.97 mL, 5.13 x 10-3 mol). The 
mixture was allowed to stir for 2 h to give rise to a white precipitate (as synthesized MP-
MSN). The solid product was filtered, washed with copious amount of deionized water and 
methanol, and dried for 12 h under high vacuum and 353 K in order to stabilize the 
mesoporous structure. Final mercaptopropyl-MSN material was obtained upon removal of 
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the CTAB surfactant template by stirring in a solution of conc. HCl in methanol (1%, v:v) for 
6 h at 60ºC . Material was then additionally washed with copious amount of deionized water 
and methanol, and it was again placed under high vacuum at 353 K to remove the remaining 
solvent from the mesopores. 
 
Loading of sulforhodamine 101 into the mesopores of MPMSN and capping with 
[Ru(bpy)2(PPh3)Cl]Cl 
MP-MSN (100 mg) was added to an aqueous solution (3 ml) of sulforhodamine 101 
(1 mg/ml) and the suspension was stirred for 24 h at RT. A separate solution (2 ml) of 
sulforhodamine 101 (1 mg/ml) was prepared containing [Ru(bpy)2(PPh3)Cl]Cl (100 mg) and 
the solution was degassed with Ar prior to heating at 80 ºC for 1 h.  After this time the 
solution containing [Ru(bpy)2(PPh3)Cl]Cl and dye molecules was added to the suspension 
containing MP-MSN and the dye, which was previously degassed with Ar. Combined 
solution was protected from light and was heated to 80 ºC for 24 h under argon. As-
synthesized material (SR101@[Ru]-MPMSN) was filtered, washed with copious amounts of 
PBS buffer (pH 7.4, I = 154 M), water and methanol and finally dried in lyophilizer. The 
filtrate was collected and the loading of the dye was determined from the difference in UV-
VIS absorption of the filtrate in PBS solution vs. starting concentration. 
 
Release kinetics measurements 
Suspensions of the dye loaded material (1 mg/ml) were prepared in PBS solution and 
the drug release was measured for sulforhodamine 101 by fluorescence emission at 595 nm 
(exc. 568 nm) and by UV-VIS spectroscopy (maximum at 568 nm) and for the release of 
capping ruthenium complex by measuring UV-VIS absorbance at 288 nm. After initial 
stirring for a prolonged time while protected from light, one of the suspensions was subjected 
to visible light irradiation with a photoreactor equipped with 3 serially connected LEDs 
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(Luxeon III Star LED - Royal Blue Lambertian, 340 mW, 700mA, emission maximum at 455 
nm, I = 1500 lux). Other suspensions of the same concentration were used for testing the 
influence of ligand substitution on dye release or were not subjected to any stimuli and were 
stirred in dark (control samples). For ligand induced dye release, calculated amount of solid 
MAHMA NONOate (Aldrich), used as a source of nitrogen-monoxide (t1/2 = 3 min), 
histidine or imidazole were added into the stirred suspension of Sr101@[Ru]-MP-MSN after 
20 h of initial stirring in dark. The concentration of ligands was first set to 20 mM and then 
after the release of the dye reached plateau, the concentration of ligands was increased to 50 
mM.  
 
Synthesis of [Ru(bpy)2(PPh3)MPA]PF6 
Synthetic procedure was analogous to the published procedure for preparation of 
[Ru(bpy)2(PPh3)GABA]PF6, (GABA = γ-aminobutyric acid).18 Namely, [Ru(bpy)2PPh3Cl]Cl 
(110 mg, 147 mmol) was dissolved in water (10 mL). The mixture was heated at 80 ºC for 
half an hour after which 3-mercaptopropionic acid (MPA)  
(469 mg, 4.42 mmol) and aqueous NaOH (4.4 mL, 1m) were added. Heating was continued 
for 3 h and the final complex was precipitated with KPF6 (0.8 mL, 1m) in ice and 
centrifuged. The product was washed twice with water (3 ml) and dried. 
 
Results and discussion 
 
Preparation of the light responsive nanocarrier initially involved synthesis of 
mercaptopropyl functionalized MSN by our well established co-condensation procedure.10 
This method has been shown to yield the material with most of the organic functional groups 
distributed along the internal surface of the mesopores. After removal of the templating 
surfactant (CTAB) by washing with a solution of HCl in methanol, the entire volume of the 
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mesopores was available for loading of the dye molecules, while mercaptopropyl groups 
were available for reaction with capping moieties (Figure 2).  
 
 
 
Figure 2. Loading of Sr101 into the mesopores of MP-MSN and capping with [Ru(bpy)2(PPh3)Cl]Cl 
 
Coordination compound [Ru(bpy)2(PPh3)Cl]Cl was used as a capping precursor for 
this DDS. At an elevated temperature in a water solution, this complex undergoes 
substitution of its chloro ligand by water molecules, which are then susceptible to 
substitution with other incoming ligands. In our system the incoming ligands are 
mercaptopropyl moieties from the internal surface of the mesopores. Coordination of ligands 
containing sulfur donor atoms to ruthenium(II)-bipyridyl complexes have been reported.19 
Analogous complex ion [Ru(bpy)3]2+ was also applied as a dye for loading into the 
mesopores of MSN-based DDS.20 However, since the size of [Ru(bpy)3]2+ ion is around 1.5 
nm,21 we believed that the analogous complex can be used as an effective capping moiety as 
well. Since the complex ion, [Ru(bpy)2(PPh3)GABA]Cl, recently showed the capability to 
release coordinated γ-aminobutyric acid (GABA) upon irradiation with visible light, we 
wanted to test the same moiety as a visible light responsive cap, which would be released 
from coordination to mercaptopropyl functionalized MSN. The dye sulforhodamine 101 
(Sr101) was chosen for loading into the mesopores because its absorption band does not 
overlap with the absorption bands of the capping ruthenium complex, which simplifies the 
release kinetics study. Additionally, Sr101 molecule has weak donor atoms and would not 
interfere with the capping process.   
 85
Nitrogen adsorption/desorption isotherms and BJH data of the materials before and 
after capping revealed that Ru(bpy)2(PPh3)- moiety ([Ru]) successfully capped the mesopores 
since it induced a decrease in BET surface area and average pore diameter in the materials 
that contained loaded Sr101 (Sr101@[Ru]-MP-MSN)  or even after capping the empty MP-
MSN ([Ru]-MP-MSN) (Figure 2, Table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. a) BET nitrogen adsorption/desorption isotherms and b) BJH average pore diameters for MP-
MSN, Sr101@[Ru]-MP-MSN and [Ru]-MP-MSN 
 
Table 1. BJH data for MP-MSN, Sr101@[Ru]-MP-MSN and [Ru]-MP-MSN 
 
 MP-MSN [Ru]-MP-MSN Sr101@ [Ru]-MP-MSN 
BET Surface area (m2/g) 1082 610 522 
BJH pore diameter (nm) 2.3 ≤2 ≤2 
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Scanning electron micrograph (SEM) of the material revealed spherical nanoparticles 
that did not change after the loading of cargo molecules and capping with [Ru]  
(Figure 4a). Low angle powder X-ray diffraction of MP-MSN showed typical diffraction 
pattern of hexagonally packed mesopores (Figure 4b). After the loading and capping, the 
XRD pattern changes due to disruption of symmetry. Energy dispersive spectroscopy (EDS) 
of the material revealed the presence of ruthenium in the amounts of 1.9 ± 0.4 wt% for 
Sr101@[Ru]-MP-MSN. Loading of the dye was determined as 71.1 μmol/g of MP-MSN. 
 
 
 
  
 
 
 
                  (a)                                                                    (b)                                 
 
Figure 4. Scanning electron micrograph (SEM) of Sr101@[Ru]-MP-MSN (a) and low angle X-ray 
diffractograms of MP-MSN and Sr101@[Ru]-MP-MSN (b) 
 
In order to measure the release of cargo molecules, 1 mg/ml suspensions of the 
material in PBS buffer (10 mM, pH 7.4) were prepared and the release kinetics were 
measured by changes in UV-VIS absorbance at 288 nm for released [Ru] and at 568 nm for 
released Sr101 as well as the change in fluorescence at 595 nm (exc. 568 nm) for Sr101. 
Suspensions were centrifuged at designated times and only the quantity of species in PBS 
solutions was measured. Figure 5a shows the comparison of UV-VIS spectra of the 
supernatants obtained from suspension that was kept in dark for 44 h and the suspension that 
was subjected to irradiation for 22 h after 22 h of stirring in dark. 
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It is evident that irradiation with visible light (455 nm) successfully releases capping 
[Ru] moiety and loaded Sr101 dye. Bands at 288 nm and 450 nm are absorptions of [Ru] 
moiety assigned to intraligand and metal to ligand charge transfer (MLCT) transitions 
respectively. Bands centered at 530 nm and 567 nm are absorptions of sulforhodamine 101. 
However, these bands are noticeably blue-shifted when compared to the typical bands of the 
dye in PBS solution which appear around 545 nm and 586 nm respectively. This 
hipsochromic shift of the UV-VIS bands of Sr101 was already reported  to occur in the case 
of adsorption on mesoporous silicate materials with 2.2 nm pore size.22  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. a) Comparison of UV-VIS spectra of the supernatants obtained from the suspension of 
Sr101@[Ru]-MP-MSN in PBS (10 mM, pH 7.4) that was stirred in dark for 44 h and the suspension that 
was subjected to irradiation for 22 h after 22 h of stirring in dark. b) Release kinetics of 
[Ru(bpy)2(PPh3)(H2O)]2+ ([Ru]H2O) and sulforhodamine 101 (Sr101) from the suspension of 
Sr101@[Ru]-MP-MSN in PBS while suspension was protected from light at all times (Dark) and for the 
suspension that was subjected to irradiation after 22 h of stirring in dark (VIS). Absorbance of [Ru]H2O 
was measured at 288 nm and absorbance of Sr101 was measured at 568 nm. Results for released 
[Ru]H2O are normalized to the total released amount of [Ru]H2O for “[Ru]H2O VIS” sample and 
released amount of Sr101 was normalized to total released amount of Sr101 for “Sr101 VIS” sample.   
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The authors explained the effect as a consequence of a change in resonance structure 
of the molecule, which in turn yields a change from a planar molecule to a pyramidal shape 
in response to concave silica surface inside the mesopores. The change in dye absorbance is 
not observed if silicate materials with larger pores were used, which reveals the necessity of a 
suitable concave curvature. Even though this behavior was reported only for Sr101 while it 
was adsorbed on MSN surface; herein we observed that the dye was also released into the 
solution in the same conformation. The result directly confirms the premise that Sr101 was 
released from the depth of mesoporous space and not just from the external silica surface. We 
further tested if only [Ru(bpy)2(PPh3)Cl]Cl would have an influence on the position of 
absorption bands of Sr101. No band shifting was observed after adding only the ruthenium 
complex to PBS solution of Sr101 even after prolonged stirring, heating or exposure to light 
irradiation. Only after addition of MP-MSN into the same solution we observed the 
hiposchromic shifting of the absorption bands of Sr101, after stirring over night (Figure S1).  
Normalized release kinetics of the capping moiety and the cargo dye are represented 
on Figure 5b. We can notice that almost zero release was observed with suspensions that 
were kept in the dark. We employed irradiation on the suspensions with visible light  
(455 nm) after 22 hours of stirring in the dark and the release of [Ru(bpy)2(PPh3)(H2O)] 
([Ru]H2O) and loaded Sr101 was clearly evident. By comparison of the normalized release 
curves for [Ru]H2O and Sr101 we observed that the release kinetics of the “cap” and the 
“cargo” molecules are identical. We believe that this behavior is a consequence of having 
both [Ru] and Sr101 inside the mesopores, and each release of the cap is followed by 
immediate release of the cargo molecules (Figure 6).  
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Figure 6. Schematic representation of visible light induced release of [Ru] caps (   ) and Sr101 (  ) as cargo 
molecules from mercaptopropyl (   ) functionalized MSN 
 
In order to prove that cleavage of thiol coordinated Ru(bpy)2(PPh3)-moiety is 
responsible for the visible light induced dye release, we synthesized analogous coordination 
compound [Ru(bpy)2(PPh3)MPA]PF6 (MPA = 3-mercaptopropionic acid). UV-VIS 
absorbance of the new ruthenium complex showed the presence of MLCT band centered at 
396 nm. After 30 minutes of irradiation of PBS solution of this complex with visible light, 
the MLCT band shifted to around 430 nm (Figure S2). This result indicates that 
[Ru(bpy)2(PPh3)H2O]2+ ion was formed due to expulsion of MPA ligand from the 
coordination sphere. 
To test the influence of different ligands on the release of the species, we monitored 
the fluorescence of the PBS supernatants (pH 7.4) after addition of MAHMA NONOate, 
imidazole and histidine (Figure 7). MAHMA NONOate is a known NO donor with a half life 
of 3 minutes at pH 7.4. As can be seen, the dye release is substantially less responsive to 
ligand induced release when compared to visible light irradiation. Even the most effective of 
the three tested ligands, nitrogen-monoxide, released only about 20 % of the total amount of 
the dye that was released by irradiation. This discrepancy between irradiation induced and 
ligand induced dye release can be explained by the need of achieving equilibrium for the 
ligand substitution reaction. That is, in order for a substitution reaction to take place, the rate 
of the reaction of capping [Ru] with the incoming ligand (L) must be faster then the 
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regeneration of [Ru]-mercaptopropyl-MSN bond. Since [Ru] moiety is already inside the 
mesopores which contains mercaptopropyl moieties along its walls, regeneration of [Ru]-
MP-MSN is favored. The probability of substitution reaction decreases further if [Ru] is 
farther inside the mesopores, which explains why the release of the dye stops soon after the 
initial release.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Comparison of the release curves of Sr101 triggered by visible light irradiation (Irr), nitrogen-
monoxide in dark (NO dark), histidine in dark (His dark), imidazole in dark (IM dark) and release from 
a control sample, with no stimulus applied (Ctrl). Suspensions were initially stirred in dark for 20 h after 
which continuous irradiation was applied (for Irr sample) or the samples were treated with 20 mM ligand 
concentration (for NO dark, His dark and IM dark samples). After additional 7.5 h the ligand 
concentration was increased to 50 mM. Top graph shows a zoom in on ligand induced dye release 
portion. Bottom graph includes visible light induced release along with ligand induced release.     
 
The release of the dye was successfully increased by increasing the ligand 
concentration from 20 mM to 50 mM, due to increased reaction probability. Strictly based on 
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comparison of stability constants,23 substitution with histidine was expected to be the most 
efficient. However, after increasing concentration of the ligands to 50 mM it is evident that 
substitution by NO was the most successful. This result can be explained by the small 
diameter of NO molecules which allows the presence of more NO molecules inside the 
mesopores, when compared to histidine or imidazole, and hence probability of substitution 
increases.  
The above results suggest that the employed cargo delivery system could be useful 
for a range of potential applications. Various stimuli responsive nanocarriers can be devised 
with the same basic triggering principle in order to fit the desired application. In addition to 
drug delivery either by externally applied light irradiation or by internal ligand induced 
triggering, we envision that the triggering principle can be useful for sensing of NO 
molecules and other relevant ligands in the environment or in biological systems.   
 
Conclusions 
 
We report on mesoporous silica nanoparticle-based supramolecular assembly for 
visible light and ligand substitution responsive release of cargo molecules. Sulforhodamine 
101 was loaded inside the mesopores of mercaptopropyl-functionalized MSN and it was 
entrapped by the presence of Ru(bpy)2(PPh3)- moieties, which were coordinated to 
mercaptopropyl functional groups. Upon irradiation with visible light  
Ru-S coordination bond is cleaved which triggers the release of capping species and loaded 
dye. Release of the cargo molecules was also shown to be responsive to ligand substitution 
by nitrogen monoxide, imidazole and histidine. We believe that this multiple-stimuli 
responsive triggering principle can be effectively applied for the construction of functional 
nanoassemblies for applications in drug delivery and sensing. 
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Figure S1. Comparison of UV-VIS spectra of Sr101 before and after addition of [Ru(bpy)2(PPh3)Cl]Cl 
([Ru]Cl) and MP-MSN 
 
 
 
 
 
Figure S2. UV-VIS spectra of [Ru(bpy)2(PPh3)MPA]PF6 ([Ru]MPA) before and after 30 minutes of 
irradiation and 30 minutes of stirring in dark 
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CHAPTER 6. GENERAL CONCLUSIONS 
 
In this dissertation, I presented my research accomplishments for the past 6 years of 
my graduate studies, in chronological order. From the beginning of my research work I 
concentrated my efforts on the construction and development of functional various stimuli-
responsive supramolecular assemblies for applications in drug delivery.  
The development of functional supramolecular assemblies is of considerable 
importance in the scientific community in recent years. From a theoretical standpoint, studies 
on organization of individual molecules into more complex structures are still in demand. 
Broad spectrum of possibilities for applications of these complex assemblies further 
increases the interest in such structures. Several examples for application of supramolecular 
systems containing mesoporous silica nanoparticles are described within this dissertation. 
We first described functional UV light responsive doxorubicin delivery system. The 
anticancer drug is positively charged at physiological conditions and it was adsorbed on 
organically modified surface of MSN. The drug delivery principle was based on charge 
repulsion between UV light-generated positively charged moieties on MSN surface and 
doxorubicin molecules. Increase in the released drug amount was also observed with increase 
in acidity. 
We also developed magnetic analogues of mesoporous silica nanoparticles. A series 
of new materials was obtained with radial and hexagonal packing of the mesopores, 
containing magnetic nanoparticles inside the core of mesoporous silicate framework. 
Loading and delivery capabilities of 9-aminoacridine (9AA) and camptothecin (CPT) from 
magnetic mesoporous silica nanoparticles (MMSN) were shown to depend on porous 
structure and presence of phenylethyl moiety inside the mesopores. Characterization of the 
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magnetic drug delivery systems and in vitro viability studies on Chinese hamster ovarian 
(CHO) cells were also presented. 
Magnetic mesoporous silica nanoparticles wee further applied for the construction of 
functional supramolecular assembly for UV light sensitive drug delivery. Anticancer drug 
camptothecin was loaded inside the mesopores of the magnetic material and it was entrapped 
by functionalized cadmium-sulfide nanoparticles though a photolabile MSN-bonded linker. 
Release of the drug was triggered upon irradiation with UV light. Cooperative cytotoxic 
activity of capping CdS nanoparticles and loaded drug was observed upon the treatment of 
CHO cells and exposure to low power UV irradiation 
Finally, we described the construction and characterization of a mesoporous silica 
nanoparticle-based nanocarrier which was capable of delivering the mesopore-loaded 
molecules upon irradiation with visible light or upon the treatment with nitrogen-monoxide, 
histidine or imidazole. Sulforhodamine 101 was used as a cargo molecule and it was 
entrapped inside the mercaptopropyl functionalized mesopores of MSN by mercapto-
coordinated Ru(bpy)2(PPh3)-moieties (bpy = 2,2’-bipyridine, PPh3 = triphenylphosphine). 
Upon exposure to aforementioned ligands or to visible light, the  
Ru-S coordination bond was cleaved and the cargo molecules were released into the bulk 
PBS solution. 
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